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Genetically engineered cells have the potential to solve the cell availability problem, 
which exists with islets of Langerhans in developing a pancreatic tissue substitute for the 
treatment of insulin-dependent diabetes (IDD).  These cells can be β cells genetically 
engineered so that they can be grown in culture, such as the βTC3 and βTC tet mouse 
insulinomas developed by Efrat et al; or, they can be non-β cells genetically engineered 
to secrete insulin constitutively or under transcriptional regulation.  As insulin secretion 
needs to be tightly regulated by glucose and other physiologic stimuli in order to achieve 
normoglycemia in higher animals and, eventually, humans, the aim of this work was to 
thoroughly characterize and improve the secretion dynamics of pancreatic substitutes 
based on genetically engineered cells. 
One issue involved with the continuous β-cell line is the remodeling of the cells 
inside an encapsulated cell system, which may affect the insulin secretion dynamics 
exhibited by the construct.  To evaluate the effect of remodeling on the secretion 
properties of the construct, we used a single-pass perfusion system to characterize the 
insulin secretion dynamics of different alginate beads in response to step-ups and downs 
in glucose concentration.  Results indicated that the secretion dynamics of beads indeed 
changed after long-term culture.  On the other hand, data with growth-regulated cell line, 
βTC tet cells, showed that the secretion profile of beads can be retained if the cell growth 
was suppressed.   
A major concern associated with genetically engineered cells of non-β origin is that 
they generally exhibit sub-optimal insulin secretion characteristics relative to normal 
xv 
pancreatic islets.  They are either secreting insulin constitutively or exhibiting slow 
responses to changes in the concentration of secretagogues.  To generate pancreatic 
substitutes with appropriate secretion dynamics based on such sub-optimal cells, a novel 
idea is proposed, which consists of sequestering these cells from the surroundings by a 
glucose-responsive material serving as a controlled barrier for insulin release.  The idea 
of improving the secretion dynamics by combining cells with materials, rather than 
relying on molecular tools, bears similarities to insulin pumps.  For an insulin pump, 
fluctuations in glucose concentration are picked up by the glucose sensor, whose output 
signal is sent to the controller that regulates the pump releasing insulin from a reservoir. 
In our proposed tissue engineered construct, the glucose-responsive material has the role 
of both the glucose sensor and controller, and the cells inside the construct serve as a 
continuously refillable insulin reservoir.  Since the cells used in the construct are of 
potentially autologous origin, they relax the immune acceptance problems intrinsic to the 
use of xeno- or allogeneic cells.  
The proposed first prototype of hybrid construct consisted of insulin-secreting cells 
sequestered from the surroundings by silicone, a 3 kDa MWCO membrane permeable to 
glucose and oxygen but not to insulin, and a material barrier sandwiched between two 
insulin-permeable membranes. Cells used in these studies were HepG2 human hepatomas 
and C2C12 murine myoblasts, both genetically engineered to secrete insulin 
constitutively.  Cells were encapsulated in approximately 700 µm in diameter alginate 
beads prior to incorporation in the device.  To study the feasibility of developing a 
cell-material hybrid pancreatic construct, a glucose-responsive material based on 
concanavalin A was used. 
xvi 
     The cell-material hybrid construct released insulin at different rates that depended 
on the glucose concentration in the surrounding medium.  Following a glucose step up, 
the con A-based material experienced a gel to sol transformation, where the sol-phase 
material was more permeable to insulin, thereby allowing a higher insulin release rate.  
Removal of glucose caused the material to change back to gel reducing the rate of insulin 
transport and thus the release of insulin from the device.  In experiments with a control 
construct, in which the material barrier consisted of an alginate sheet, the rate of insulin 
release from the device did not respond to glucose concentration changes.  These initial 
secretion experiments indicate feasibility of engineering a properly secreting pancreatic 
substitute based on sub-optimally secreting cells.   
 As the con A-based material used in the proof-of concept experiments exhibited 
glucose sensitivity far beyond the physiologic range, the last part of the thesis attempt to 
addresses this issue by using PEGylated con A molecules.  Material formed with 
PEGylated con A has improved glucose sensitivity, and the hybrid construct containing 
modified con A-based material also released insulin in response to step changes of 
glucose concentration closer to physiological range.  Although there is still much work 
to be done with the development of cell-material hybrid construct, we have successfully 
presented a new set of methodologies for engineering a pancreatic substitute potentially 









Diabetes mellitus (DM) is a serious health problem affecting more than 18.2 million 
people and costing over 132 billion dollars a year in the United States.  The cause of the 
disease has been associated with both genetics and environmental factors such as obesity 
and lack of exercise.  Unfortunately, as shown by the increased rates of obesity and the 
trend toward more sedentary lifestyles, its incidence will continue to grow.  Patients 
who suffer from DM are characterized by abnormally high levels of blood glucose 
because the body does not produce or properly use insulin.  About 31 % [1] of DM 
patients are taking insulin to maintain their healthy state, and these populations are so 
called the insulin-dependent diabetics (IDD).  However, a study done by Diabetes 
Control and Complications Trial Research group  has shown that taking one or two shots 
of insulin a day is not enough to prevent long-term complications associated with 
hyperglycemia, including retinopathy, nephropathy, neuropathy, and cardiac and 
peripheral vascular disease [2].  A proper regimen suggested in that study included three 
or more insulin injections per day or continuous subcutaneous insulin infusion, in 
addition to frequent blood glucose testing to achieve normoglycemia.  Clearly, these 
treatments are cumbersome to the patient, and they also have the adverse effect of 
increasing the probability of severe hypoglycemic episodes two to three fold relative to 
traditional insulin therapy.  
Insulin plays a major role in regulating blood glucose level, as blood-glucose level 
fluctuates depending on the caloric intake and expenditure, too much or too little insulin 
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in the body could lead to hypo- or hyperglycemia, respectively.  To prevent both 
conditions, an insulin-delivery system should be well designed to mimic how β cells 
release insulin, in which cells not only secrete insulin at a low rate during basal blood 
glucose but also respond quickly to the increase and the decrease of blood-glucose level.  
Based on this concept, closed-loop insulin delivery systems, consisting of a glucose 
sensor, a controlled pump, and an insulin reservoir, were proposed since the 80s’.  
However, some technical problems including, among others, the longevity and the 
stability of sensor, have not yet been overcome successfully. 
Cell-based therapy has long been considered as the most promising approach in 
treating IDD.  One of the success trials is the islet transplantation based on Edmonton 
protocol.  About 80% of patients who received islet transplantation have become insulin 
independent up to a year [3].  However, in this treatment, patients are required to take 
lifetime immunosuppressive drugs, which could cause severe side effects after long-term 
usage.  It is still up to debate whether the benefit of islet transplantations could outweigh 
its risk, however, based on the number of donors available per year, it is estimated that 
only 0.5% of patients are able to receive the treatment [4].  Thus, an alternative cell 
source needs to be pursued.    
Various cell sources have been proposed that could be categorized into three major 
areas: xenogeneic islets, insulin secreting cells derived from stem cells, and genetically 
engineered cells.  Each of the cell sources has limitations that need to be overcome.  In 
this thesis, the focus is on the insulin secretion properties of genetically engineered cells.  
Two types of cells were studied: continuous β-cell lines and the cells of non-β origin.  
Most of the currently available continuous β-cell lines have been derived from 
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transgenic animals, such as the βTC family developed by Efrat et al [5].  These cells are 
easy to culture and propagate, and have high insulin secretion rate with glucose 
responsiveness.  Because developing a human continuous β-cell line has been proven to 
be quite challenging, this approach would eventually be adapted as xenogeneic cell 
transplantation.  To prevent immune rejection, cells will need to be encapsulated in a 
semi-permeable membrane that allows low molecular-weight nutrients and insulin to pass 
through but not the penetration of the host cells or large molecular-weight antibodies.  
One of the promising approaches is to encapsulate these cells in alginate/ poly-L-lysine/ 
alginate (APA) microbeads.  Nonetheless, as the cells would continue to proliferate after 
encapsulation, extensive cell-mediated remodeling could occur, including the 
development of nutrient gradients within the beads, degradation of the supporting matrix, 
and accumulation of cell death byproducts.  All of these could eventually affect cellular 
phenotype or implant performance.  Since insulin secretion dynamics are critical at 
restoring normoglycemia in vivo, especially in higher animal models, in Chapter 3 of this 
thesis, we built a perfusion system to address the effects of long-term culture on the 
secretion profile of alginate-encapsulated βTC cells.     
Another genetically engineered cell type studied in this thesis is cells of non-β origin. 
Various cell types can be used, such as hepatocytes and myoblasts, hence less concern of 
cell availability.  Cells can be taken as biopsy from a patient and genetically engineered 
ex vivo to become insulin-secreting cells.  Thus, these autologous cells relax the 
immune-acceptance problems intrinsic to the use of xeno- or allogeneic cells.  
Nonetheless, as β cells are a highly differentiated cell type with a sophisticated phenotype 
in regulating insulin release according to metabolic cues, researchers have faced 
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tremendous challenges in using molecular tools, such as gene manipulation, to engineer 
these cells to have a proper insulin secretion dynamics:  cells are either secreting insulin 
continuously or exhibiting sluggish kinetics in response to stimuli [6, 7].   
The other parts of the thesis proposed a novel approach of incorporating a 
glucose-responsive material to improve the secretion profile of genetically engineered 
cells of non-β origin.  Glucose-responsive material is a type of smart hydrogel that has 
different insulin-permeability under different glucose concentrations: at low glucose 
concentrations, the material is in a gel state that exhibits low insulin permeability, 
whereas at high glucose levels the material becomes a sol that exhibits a higher 
permeability to insulin.  The time constant of the gel to sol and of sol to gel 
transformations is shorter than the (infinite) time constant of constitutively secreting cells 
or the (long) time constant of transcriptionally regulated cells.  Through proper 
engineering, we can then develop a cell-material hybrid construct in which the kinetics of 
material transformation determine the kinetics of insulin release from the entire device, 
and hence improve the secretion characteristics exhibited by the cells alone.  
As glucose-responsive materials have already been developed for the use of glucose 
sensor and insulin delivery, the proof-of-concept experiment began with identifying a 
type of glucose-responsive material suitable for associating with insulin-secreting cells.  
Selection criteria were listed, such as glucose specificity, kinetics of phase transformation, 
function under physiologic conditions, and capability of regulating insulin secreted by the 
cells, in other words: insulin does not need to be modified.  Table 1.1 summarizes the 
results of the comparisons among three major types of glucose-responsive materials.  
Consequently, concanavalin A (con A)-based material, although not ideal, seems to be the 
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most suitable material for developing a cell-material hybrid construct.  In CHAPTER 4, 
a diffusion chamber was built to test the glucose-responsiveness of con A-based material, 
and a preliminary experiment was done with encapsulated βTC3 cells as insulin source to 
test our hypothesis:  glucose-responsive material can be used to control insulin released 
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The research done in CHAPTER 4 leads to the development of the first prototype of 
cell-material hybrid construct.  Cells of non-β origin, human HepG2 hepatomas and 
murine C2C12 myoblasts, were genetically engineered to become constitutively 
insulin-secreting cells.  By incorporating these cells in a hybrid construct containing con 
A-based material, we obtained a device that released insulin in response to glucose 
square-wave changes.  The details are describes in CHAPTER 5.  Although we were 
able to prove our concept by using con A-based material as a controlled barrier for the 
insulin released by the cells, problems exist with the material that need to be overcome 
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prior to any in vivo experiments, which include glucose sensitivity, stability, and 
biocompatibility.  
 In terms of glucose sensitivity, as the glucose responsiveness of con A-based 
material arises from the competitive binding reaction between free glucose and pendent 
glucose on a polymer chain toward con A binding sites, it is possible to improve the 
sensitivity of the material by using different types of polysaccharides or modified con A 
molecules that have different glucose binding affinity.  For the latter, Park et al [8] 
reported that one can increase the binding affinity of con A towards free glucose up to 5 
fold through PEGylation of con A.  PEGylation is a well established tool in improving 
the biocompatibility and the stability of proteins, as well as a substrate for tethering 
protein to the surface of biomaterials.  Inspired by these positive results from 
PEGylation, studies in CHAPTER 6 aimed at improving the glucose responsiveness of 
con A-based material through the use of PEGylated con A molecules.  Other approaches 
taken to improve the properties of con A-based material are presented in APPENDIX A.1 
and A.2. 
 General information on IDD treatment, including current therapies, development of 
glucose-responsive materials, and cell-based approaches are reviewed in CHAPTER 2, 













2.1 Diabetes Mellitus  
Diabetes mellitus (DM) is a metabolic disorder associated with insufficient insulin 
secretion in response to glucose and tissue insensitivity to insulin action.  It is 
recognized as one of the most expensive illnesses in the heath-care system, with 18 
million people affected and 132 billion dollars spent in the United States of America [9].  
Two main types of diabetes are Type 1 diabetes and Type 2 diabetes.  Type 1 diabetes 
comprises 5-10% of DM and often develops in patients of young age and thus is 
commonly called “juvenile diabetes”.  It is an autoimmune disorder in which activated 
T-cells infiltrate the islets of Langerhans and destroy the insulin-producing β cells.  The 
consequence of β-cells destruction causes the Type 1 diabetic patients to be completely 
insulin deficient, and as a result, patients are required to take daily insulin injections to 
maintain survival.  Type 2 diabetes is the most common type of diabetes, which affects 
90-95% of diagnosed diabetes.  Its exact cause is still uncertain but is associated with a 
combination of genetic and nongenetic factors, the latter including increasing age, high 
caloric intake, and overweight.  In contrast to type 1 diabetes, patients with type 2 
diabetes usually produce some insulin, but their body cells cannot use it efficiently 
because the cells are resistant to insulin.  By losing weight, controlling diet, exercising, 
and taking oral medications, it is possible for a patient to overcome the disease.  
Nonetheless, some type 2 diabetes patients gradually develop into insulin dependency, 
which is associated with impaired β-cell function, and hence require daily insulin 
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injections to stay alive.  Type 1 diabetics together with type 2 diabetics who are required 
to take insulin injections are called insulin-dependent diabetics (IDD), and they account 
for about 31 % of DM cases [2].  
In a healthy individual, β cells secrete insulin in response to blood glucose levels.  
Between meals or through out the night when the blood glucose is at the basal level, 
insulin is secreted continuously at a low rate.  After a meal, cells adjust their insulin 
secretion rate according to the higher blood glucose concentration, with a threshold value 
at 4 mM, a half-maximal response at 8 mM, and a maximal rate at 15 mM.  The kinetics 
of insulin secretion is very rapid both upon stimulation and removal of glucose.  As the 
blood glucose level fluctuates a lot depending on a person’s caloric intake and 
expenditure, patients who take only insulin injections are not able to maintain euglycemia, 
and eventually suffer from long-term complications such as heart, kidney, and nervous 
system diseases, stroke, and blindness.  
Data from the Diabetes Control and Complications Trial (DCCT) [1] indicated that 
intensive treatment of type 1 diabetes with control of blood glucose significantly delays 
the onset of complications in diabetic patients such as retinopathy, nephropathy, and 
neuropathy by 50 to 75% when compared with conventional treatment.  In contrast to 
the conventional treatment, which involves no more than two insulin injections per day, 
intensive therapy in the DCCT included multiple injections of insulin three or more times 
per day or continuous subcutaneous insulin infusion (CSII) by external pump, in addition 
to frequent blood glucose self-monitoring.  However, the improvements of intensive 
therapy were associated with threefold increase in the risk of hypoglycemia and incidence 
of becoming overweight [10].  Hence, various alternatives are being developed to seek a 
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better control of insulin delivery that would eventually mimic the physiologic response of 
β cells.  Following is a short overview of approaches and limitations of available 
treatments such as multiple insulin injections and insulin pumps, and the potential of 
cell-based therapies such as islet transplantations or the implantation of other 
insulin-secreting cells. 
 
2.2 Multiple daily injections and insulin pump 
In order to mimic the insulin secretion characteristics of β cells, in which a basal 
insulin secretion is maintained between meals and during bedtime, and bolus insulin 
release occurs after a meal, patients need a combination of both long-acting and 
short-acting insulin.  The long-acting insulin, such as NPH, is used to provide the basal 
insulin needs.  The short-acting insulin, such as Lispro, is taken before the meals for the 
postprandial insulin [11].  With this regimen, a patient needs more than three times of 
insulin injections per day, frequent glucose monitoring that involves finger poking, and 
the awareness of diet composition to determine the dosage required to prevent the event 
of hypo-or hyperglycemia.  Undoubtedly, the amount of time and money involved with 
daily insulin-injections could deprive one’s quality of life.   
Another type of insulin delivery is the continuous subcutaneous insulin infusion 
(CSII) by external pumps.  These are the battery-operated devices that function by 
delivering regular insulin through a needle inserted in the skin.  Depending on a 
patient’s need, the pump is programmed to deliver insulin at a basal rate during the 
fasting state, and before meals it can be programmed to infuse bolus doses of insulin to 
cover the carbohydrate content in the food.  Although CSII seems to provide patients 
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with a better lifestyle, it poses the risks of skin irritation, infection at the infusion site, and 
pump failure, and has also the disadvantages of the high cost and limitation of physical 
activity because pumps can be jostled loose from the body [12].     
Under those circumstances, an implantable insulin pump (IIP) that could 
continuously deliver insulin in response to glucose is considered as another possible 
replacement of insulin injections.  An IIP should consist of three components: a 
pumping system that stores and releases insulin; a glucose monitoring system; and an 
algorithm that links the two systems together to ensure the right amount of insulin being 
delivered.  Figure 2.1 shows the basic design of a typical implantable insulin pump.  
The pump is surgically implanted in a subcutaneous pocket in the lower abdomen under 
local anesthesia.  A catheter linked to the pump is advanced through the rectus muscle 
into the peritoneal cavity.  The peritoneal route is preferred over the subcutaneous route 
because insulin is absorbed by the portal system, which is more similar to pancreatic 
insulin secretion.  Because insulin delivered would be adjusted based on the signal sent 
by the glucose sensor, the success of insulin-delivery from such system relies on the 
development of a continuous glucose-monitoring system.  However, most of the glucose 
sensors developed up to date face the problems of short life-time, low stability, and 
problems of accuracy, thus limiting the development of implantable insulin pump.  
Besides the issues of developing a functional glucose-sensor, there exist other concerns 
with IIP, such as pumps require significant maintenance in that they need to be refilled 
and replaced; possible complications also involve catheter blockage, pump-pocket events, 
and pump mechanical failures.  These, as well as the high cost of the device, limit the 







Figure 2.1 Schematic of implantable insulin pump.
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2.3 Glucose-responsive material 
As mentioned above, the major hurdles for an insulin pump to function properly are 
the performance of the glucose sensor and issues with the pumping system.  To simplify 
a closed-loop insulin delivery without these two major components, another closed-loop 
system composed mainly of a glucose-responsive material has been proposed.  In such a 
system, so called the self-regulated insulin-delivery, the glucose-responsive material has 
both roles of a glucose-sensor and a controlled barrier.  Based on this concept, various 
novel designs, including bulk hydrogels, matrix systems, and membranes, were proposed 
for glucose-regulated insulin delivery.  The performance of such systems differs based 
on the types of glucose-sensing mechanisms intrinsic to the materials used.  The 
following paragraphs provide brief descriptions of three major types of 
glucose-responsive materials based on: glucose oxidase (GluOx), phenyl boronic acid 
(PBA), and concanavalin A (con A).  
 
2.3.1 Material based on enzymatic reactions of glucose-oxidase (GluOx) 
GluOx is a glucose-specific enzyme that catalyzes the following chemical reaction: 
Glucose+O2+H2O→Gluconic acid + H2O2 
Based on this enzymatic reaction, when a system containing GluOx is exposed to a 
higher glucose-concentration, the pH of the surrounding solution decreases due to the 
production of gluconic acid.  Owing to this unique relation between pH and glucose 
concentration caused by the GluOx, different types of GluOx-containing insulin delivery 
systems have been proposed and are briefly described below. 
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2.3.1.1 Insulin solubility and pH   
Normal insulin has an isoelectric point of 5.3, so when it exposed to pH lower than 
the physiologic pH of 7.4, a decrease in its solubility results, thus reducing its release rate.  
Langer et al [15, 16] modified insulin with more basic groups to raise its isoelectric point.  
The resulted tri-lysine insulin had an isoelectric point of 7.4 and thus its solubility 
increased with a decrease of pH.  When incorporating tri-lysine insulin with GluOx in 
hydrophobic polymers such as ethylene-vinyl acetate copolymer (EVAc), the 
pH-lowering effect caused by the reaction of GluOx in response to the external increase 
of glucose led to an increase of the solubility of tri-lysine insulin, thus raising the rate of 
insulin release.  
 
2.3.1.2 pH-responsive polymer 
A pH-responsive polymer is a type of hydrogel that swells or collapses depending on 
the surrounding pH and can be classified into two categories: anionic and cationic 
hydrogels, depending on the nature of ionizable moieties on their backbones.  Anionic 
gels usually contain acid groups and swell at high pH and collapse at low pH (unless 
specified, the pH range discussed in this paragraph is between 7 and 4).  When 
incorporating both GluOx and insulin in a matrix system of anionic gels, the pH-lowering 
effect from GluOx caused gels to collapse or shrink and consequently enhanced the 
insulin-release rate due to the “squeezing” action posed by the hydrogel (Figure 2.2) [17].   
In another similar design, anionic pH-sensitive material based on acrylic acid was grafted 
to porous membranes with immobilized GluOx [18, 19] (Figure 2.3).  Under low 
glucose concentration and at pH 7, the polymer chains are expanded and thus they 
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effectively close the membrane pores.  Upon exposure to high glucose, gluconic acid 
generated by the reaction of GluOx and glucose lowered the pH and resulted in the 
polymer chains collapsing.  Therefore, the pores were open for the diffusion of insulin.  
Cationic pH-sensitive hydrogels, usually composed of amine groups, swell at low 
pH and shrink at high pH.  A typical glucose-responsive hydrogel based on the cationic 
pH sensitive material and GluOx is shown in Figure 2.4 [20, 21].  Under low glucose 
concentration, the material is in a collapsed state with small pore size that restricts the 
diffusion of insulin.  When exposed to high glucose, the decrease of pH caused by the 
generation of gluconic acid causes the gel to swell and as a result, increases the insulin 
release rate.   
Based on the expansion properties of the glucose-responsive material composed of 
cationic pH-sensitive material and GluOx, Siegel and coworkers [22] proposed an 
implantable “mechanochemical” device as shown in Figure 2.5.  The device consists of 
three chambers: chamber I is composed of the expandable glucose-responsive material 
just described, chamber II contains aqueous fluid, and chamber III contains insulin 
solution.  When the device is exposed to a higher glucose, the swollen hydrogel 
generates forces that cause the valve at the chamber III to open up, thus releasing the 
insulin from chamber III.   

























Figure 2.2 Mechanism of glucose-responsive material based on anionic pH-responsive 
material and glucose oxidase (GluOx).  In the absence of glucose, the gel is in a swollen 
state with the insulin entrapped inside the matrix.  In the presence of glucose, the 
GluOx-glucose reactions cause a decrease in the pH, which leads to a collapse of the 





























































Figure 2.3 Mechanism of glucose-responsive membrane based on anionic pH-responsive 






























Figure 2.4 Mechanism of glucose-responsive membrane based on cationic pH-responsive 

































Figure 2.5 Schematic of “mechanochemical” insulin delivery device proposed by Siegel 




























2.3.1.3 Polymer erosion 
Another approach proposed by Heller [23] is the introduction of a pH-sensitive 
bioerodible polymer with GluOx.  This system is based on the fact that the resultant 
lowered pH triggered by GluOx can enhance polymer degradation that leads to the 
release of insulin from the polymer.  Another similar approach proposed by Uchiyama et 
al [24] is to incorporate a phospholipid polymer that would be degraded upon exposure to 
H2O2, the side product of glucose oxidation reaction.  Such mechanism is depicted in the 
Figure 2.6.  
The development of glucose-responsive material based on GluOx still faces many 
challenges.  First of all, the stability of GluOx diminishes with time.  Of concern also 
is the production of hydrogen peroxide during the reaction, which has been shown not 
only to be toxic to the cells but also to deactivate the enzyme.  Secondly, the reaction of 
GluOx and glucose is oxygen limited, hence the decrease of pH is also limited within a 
small range that could affect the glucose-responsiveness of the polymer.  A potential 
solution involves the incorporation of another enzyme: catalase.  Catalase can alleviate 
the depletion of oxygen and the accumulation of hydrogen peroxide by the following 
reaction:   
H2O2→1/2 O2 + H2O 
Although adding the catalase into the system improved the properties of GluOx based 
polymer [25], this type of the material still has major problems of sluggish kinetics in 
phase changes and is unable to recover to its original conformation after exposing to 








Figure 2.6 Schematic representation of insulin release from glucose-oxidase containing 
polymer stimulated by glucose.  Figure adapted from [24] 
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2.3.2 Material based on Phenyl-boronate (PBA) 
In an aqueous solution, phenylboronic acid and its derivatives have the ability to 
reversibly bind dihydroxyl molecules such as glucose.  The complex between PBA and 
a polyol compound can be dissociated if another polyol compound is introduced.  Based 
on this unique diol binding property, Shiino et al [26] bound a saccharide-modified 
insulin (G-insulin) onto a PBA gel column.  Because glucose can compete with 
G-insulin for the PBA diol binding sites, when the column was eluted with glucose 
solution, the release rate of G-insulin from the column increased relative to the rate 
detected under glucose-free elution.   
PBA can also form a complex gel with a polyol polymer such as poly(vinyl alcohol) 
(PVA).  A copolymer synthesized by Kitano et al [27] from PBA and PVA exhibited 
glucose-dependent viscosity changes and its mechanism is demonstrated in Figure 2.7.  
Under low glucose concentration, pendant PBA formed a highly viscous gel with PVA, 
and insulin was entrapped inside the matrix.  When glucose was added to the hydrogel, 
the gel swelled due to a decrease in the cross-linking density caused by the substitution 
reaction of glucose with the pendant hydroxyl groups of the polymer toward borate 
groups.  This hence led to the release of insulin from the matrix.  
PBA exists in equilibrium between the uncharged and the charged form as shown in 
Figure 2.8.  The complex structure formed by the uncharged borates and glucose is 
susceptible to hydrolysis, hence it is not stable.  As only charged borates can form a 
stable complex with glucose, adding glucose into the system can shift the equilibrium in 
the direction of increasing charged phenylborates, which then influence the solubility of 
the polymer composed of PBA.  Based on this glucose-dependent solubility change, 
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Kataoka et al [28, 29] prepared a copolymer from poly(N-isopropylacrylamide) 
(PNIPAAm) and PBA, which exhibited a sharp transition in the swelling ratio when 
exposed to high glucose concentration.  On and off regulation of insulin release from 
such hydrogel was successfully demonstrated with stepwise changes in the glucose 
concentration.    
The advantage of PBA-based polymer is the fact that it is totally synthetic and does 
not involve a protein that tends to lose its activity with time.  Nonetheless, most of the 
systems described above were functional under physiologically irrelevant conditions such 
as high pH (above 9) and temperature.  To alleviate this, it has been proposed to  
incorporate amine groups into the PBA-based polymer [30] or to change the chemical 
structure of PBA [31].  However, since PBA binds to most of the molecules with diol 
structure, a PBA-based polymer is not highly specific to glucose, and this could be a 













       
 
 
Figure 2.7 Schematic of glucose-responsive material based on PBA and poly(vinyl 
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2.3.3 Material based on Concanavalin A (Con A) 
Con A, a globular plant protein isolated from jack bean, is composed of identical 
25,500 molecular weight asymmetric subunits (the amino acid sequence contains 238 
residues) arranged in dimeric, tetrameric and higher-order forms.  The arrangement of 
these proteins is affected by the solution properties such as pH, temperature, ionic 
strength, and salts present in the solution.  For instance, at pH 5, most con A molecules 
exist as a dimer, while at pH 7 con A forms a tetramer.  Con A generally binds to 
saccharides containing α-D-mannose or α-D-glucose residues and appears to recognize 
terminal as well as internal saccharide residues.  The hydroxyl groups that are most 
critical for binding to con A are situated at positions C-3, C-4, and C-6 of the pyranosyl 
ring system.  Any modification of these hydroxyl groups drastically reduces or abolishes 
completely interaction with con A.  For example, Con A has a very small affinity 
towards galactose because the orientation of the hydroxyl group at the C-4 position in 
galactose is different from that in glucose (Figure 2.9) [32].   
Due to its saccharide-binding ability, con A has been widely used for purification and 
characterization of carbohydrates, in the development of glucose-senor, and as a possible 
candidate for glucose-responsive insulin carrier.  Kim et al [33] bound the glycosylated 
insulin onto con A beads and enclosed those in a polymeric membrane device that is 
permeable to glucose and glycosylated insulin but not to con A beads.  Due to the 
competitive binding reaction between free glucose and glycosylated insulin towards con 
A binding sites, exposing the device to high glucose concentration resulted in the release 
of glycosylated insulin from the device. The release of insulin stopped after glucose 
concentration was lowered.  
25 
Other research groups have focused on the development of glucose-responsive 
hydrogel by mixing con A with polysaccharides [34-36].  The mechanism is shown in 
Figure 2.10.  Con A, with four glucose-binding sites, functions as a crosslinker for 
glucose-containing polymer chains, and the mixture of polysaccharides and con A hence 
forms a viscous hydrogel.  In the presence of free glucose molecules, the competitive 
displacement of the glucose-bearing polysaccharide by free glucose from con A occurs, 
thus the gel viscosity falls and it becomes sol.  Upon the removal of glucose, the sol 
form of the material is transformed back to gel.  The insulin permeability of con 
A-based hydrogel is thus affected by the presence of glucose.  Glucose sensitivity of a 
con A-based glucose-responsive hydrogel is affected by several factors, including the 
type of polysaccharide used in the system and any modification of the con A molecules. 
A major concern of using con A-based glucose-responsive material is the 
immunogenicity of con A molecules.  Through specific interaction with saccharide- 
containing cell surface receptors, any leaked con A from the system can cause immune 
response by activation of T-lymphocytes [37] and also lead to cell death.  Moreover, as 
con A is the glucose-sensing element in the hydrogel, loss of con A would compromise 
the stability of the hydrogel.  Therefore, various groups have proposed different 
approaches for tethering con A to the polysaccharide chain [38-40], but results thus far 
are not ideal, such as the glucose sensitivity of the resulting material is not close to the 




























2.4 Cell based therapy for IDD 
2.4.1 Regulation of insulin production and secretion in β cells 
Before going into the details of cell-based therapy for IDD, it is important to 
understand how the β cells regulate their insulin secretion.  Figure 2.11 is a simple 
illustration indicating that β cells use glucose to regulate insulin secretion in a very 
complex manner from activation of biosynthesis, and processing of the insulin molecules, 
to the exocytosis of insulin.  
At the transcription level, the activation of the insulin promoter requires the binding 
of a unique set of transcription factors that can only be found in β-cell nucleus, hence, 
other cell types do not contain the same set of nuclear proteins that can activate 
transcription [41].  Although the mechanism is not fully understood, glucose does play a 
key role in the activation of the preproinsulin gene [42].  Total preproinsulin mRNA in 
the β cells usually remains at a constant level during short-term glucose stimulation (less 
than 2 hours) [43].  An additional degree of transcriptional regulation can be seen when 
longer glucose stimulation period (eg. > 4 hours) was implemented.  In other words, the 
increase of proinsulin biosynthesis during short-term glucose stimulation is dominated at 
the translational level, which includes the recruitment of preproinsulin mRNA from an 
inert cytosolic pool to translationally active membrane bound polysomes on the rough 
endoplasmic reticulum, enhancement of mRNA stability, increase in translation initiation 
and elongation, as well as elevation of biosynthesis of prohormone convertase enzymes 


































After introduction of glucose stimulus, a significant glucose-induced proinsulin 
biosynthesis can be observed by 20 minutes, reaching a maximum rate by 60 minutes 
post-stimulate [47, 48].  The off-rate of proinsulin biosynthesis is relatively slow, taking 
more than 1 hour to return to basal level [48].  Overall, the kinetics of proinsulin 
biosynthesis do not correlate well with those of insulin secretion from the β cells.  
Moreover, the threshold concentration of glucose required to stimulate insulin secretion is 
4 to 6 mM, but that to stimulate proinsulin biosynthesis is only 2 to 4 mM [49].  
Therefore, it is fair to say that the increase of insulin biosynthesis in the cells is to 
compensate for any loss of insulin by exocytosis, and the fast kinetics of insulin release 
are determined by the secretory pathway.  
    When exposed to rapid and sustained glucose stimulation, β cells exhibit a biphasic 
insulin secretion profile: the first phase is the prompt release of insulin that peaks shortly 
after stimulation and declines rapidly to a low level; the second phase consists of a 
gradually increasing rate 30 minutes after glucose stimulation.  During the first phase, 
glucose enters the β cells via high-capacity GLUT2 glucose transporter, which allows fast 
equilibration of glucose across the plasma membrane.  Glucose is then phosphorylated 
by glucokinase (GK), the first enzyme in the glycolytic pathway.  GK has a Michaelis 
constant Km of 8 mM for glucose, which explains the concentration dependence of the  
β cell response to glucose in the physiological range [50, 51].  Further metabolism of 
glucose leads to an elevation of the ATP/ADP ratio, which causes the closure of K+ 
channels and depolarization of β cells [51].  This then activates Ca2+ channels, increases 
the entry of Ca2+, and triggers the exocytosis of the immediately releasable pool of 
granules.  The immediately releasable granules comprise approximately 0.5% of total 
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granules available, the remaining granules are categorized into morphologically docked 
(granules that are in contact with the plasma membrane) and reserve granules.  These 
granules are responsible for the second phase insulin secretion, but the mechanism is not 
fully understood [52, 53]. 
 
2.4.2 Islet transplantation 
Islet transplantation has become one of the most promising treatments for insulin- 
dependent diabetes since the development of Edmonton protocol published in 2000.  
About 80% of the patients who received this treatment maintained insulin-independence 
with reduced occurrences of hypoglycemia up to a year.  The key elements that led to 
the success of Edmonton protocol include the avoidance of glucocorticoid 
immunosuppressive drugs that might damage β cells and increase insulin resistance, the 
optimization of islet function by limiting cold ischemia and immediate transplantation, 
the usage of sufficient islets isolated from at least two donors, and transplantation of 
islets into the liver via the portal vein [3].  Despite the exciting outcomes, this protocol 
is restricted to patients with severe hypoglycemic episodes due to the following two 
reasons.  First, patients who received the islet transplantation are exchanging the burden 
of frequent insulin injections with the risk of taking lifetime immunosuppressive drugs, 
which are known to give the short-term side effects of severe mouth ulceration, 
hypertension, weight loss, anemia, and elevated cholesterol, and their long-term side 
effects may have not yet been revealed [54].  Second, based on the large patient 
population and available donors per year in North America, it was estimated that only 
0.5% of type 1 diabetes patients can be treated with islets transplantation [55]. This 
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number was approximated without counting 300,000 new-diagnoses per year in North 
America and excludes the fact that some patients require more than two islet 
transplantations.  Using islets from other species, such as pig, might solve the 
availability problem, but the concern of porcine endogenous-retrovirus (PERV) 
transmission [56] and difficulties in ensuring good-manufacturing production of porcine 
islets would halt the clinical application.  In addition, there is still a long way to resolve 
the immune-acceptance problems intrinsic to the use of xenografts.  Immunoprotection 
of xenogenic or allogenic cells by encapsulation might reduce the need for 
immunosuppressive drugs, however, small cytokines can still pass through the 
semi-permeable membrane and cause cell death; hence it is difficult to achieve complete 
protection with encapsulation [57].  As the long-term goal of cell-based therapies is to 
completely correct the diabetic state with unlimited donor sources and without 
immunosuppressive drugs, a better alternative cell source needs to be sought.  Other 
possible cell sources include: 1) stem cells 2) genetically engineered continuous cell lines 
and 3) cells of non-β origin.  Each of these is described below. 
 
2.4.3 Stem cells 
In the area of regenerative medicine, stem cells constitute the most promising cell 
source because of their ability of self-renewal and the capability of differentiating into 
different cell types.  With limited success due to the lack of complete knowledge in stem 
cell biology, both human and mouse embryonic stem cells (ES) and adult stem cells have 
been differentiated into insulin-secreting cells.  With adult stem cells, normaglycemia 
was restored in non-obese diabetic mice that received islet-like cells differentiated from 
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mice pancreatic ductal epithelial cells [58].  Bonner-Weir et al [59, 60] were able to 
differentiate the duct tissue obtained after human islet isolation into glucose-responsive, 
insulin-secreting, islet-like structures.  These two findings provide the possibility of 
using patients’ own stem cells to restore their damaged β-cells.  However, issues that 
need to be addressed before considering this approach are as follows:  the reported 
relatively low insulin content in differentiated β-like cells, slow proliferation and 
differentiation rate with adult stem cells, and most importantly, there is a great chance 
that the autoimmunity in a type 1 diabetic patient will still recognize the implant and thus 
immunosuppression or encapsulation will be needed. 
  When compared to adult stem cell, ES cells have higher proliferation rate and 
differentiation capacity.  Both human [61] and mouse ES [62, 63] cells have been 
differentiated into insulin-secreting cells either by genetic manipulation or by controlling 
the culture conditions.  Moreover, STZ-induced diabetic mice implanted with mouse 
ES-derived insulin-secreting cells achieved normoglycemia for up to 16 weeks [64].  
Apart from these exciting results, differentiated β-cells from ES cells would possibly 
encounter the autoimmune rejection in type I diabetes and hence immunosuppression or 
encapsulation is again required.  Furthermore, the potential threat of teratoma  
formations from the undifferentiated cells within the ES-derived graft [65, 66] and the 
ethical issues with human ES cells would probably halt the clinical applications of 
ES-derived cells for a long time.     
 
2.4.4 Continuous cell lines 
Because of the availability issue with islet transplantation, and the difficulties in 
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using cells derived from stem cells, one of the promising approaches is to expand β cells 
through the development of continuous β cell lines.  Efrat et al [67] have developed a 
family of continuous β cell lines by expressing the SV40 large T-antigen (Tag) under the 
control of the insulin promoter in transgenic mice.  One of the early cell lines, βTC3, 
can be propagated easily in culture, secretes high amounts of insulin, and exhibits a 
secretion profile similar to that of mouse islets (See Chapter 3).  However, due to its 
high expression of GLUT1 instead of the GLUT 2 glucose transporter and of hexokinase 
instead of glucokinase, βTC3 cells are hypersensitive to glucose and would not be 
applicable for implantation [68].  Later cell lines such as βTC6 were able to secrete 
insulin in response to physiologic glucose concentrations, but their ability to secrete 
insulin diminished with time in culture [69].  Due to the fact that increasing passage 
number of continuous β cell lines could cause them to lose insulin secretion properties, 
and also as one needs to prevent overgrowth in vivo, another cell line, βTC tet, was 
developed to allow control over the growth [70].  The expression of Tag gene in such 
cells was under control of the regulatory elements of the bacterial tetracycline (tet) 
operon:  in the absence of tetracycline, βTC-tet can be propagated easily in culture; in 
the presence of tetracycline, cells undergo growth arrest with an increase of insulin 
secretion rate.  βTC-tet cells also exhibit a secretion profile similar to islets (see Chapter 
2) and display proper glucose-responsiveness.  Animal studies with βTC tet cells have 
shown some promising results in restoring normoglycemia (Weber et al, data not 
published).    
Developing human insulinoma cell lines has proven to be more challenging than 
anticipated.  Even if one successfully develops a human cell line with proper insulin 
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secretion characteristics, immunoprotection of these cells through cell-encapsulation in 
semipermeable membranes is still a must to prevent graft failure intrinsic to the use of 
allogeneic cells and possible autoimmunity towards β cells, and concern of tumorigenic 
phenotype of human β cell line.   
One of the promising approaches is to encapsulate these cells in 
alginate/poly-L-lysine/alginate (APA) microbeads.  Studies with βTC3 and βTC-tet 
without growth suppression have shown that cells continued to grow post-encapsulation, 
and the growth pattern inside the microbeads depended on the alginate composition and 
oxygen availability.  For instance, with βTC3 cells, no significant growth suppression 
occurred in beads made of high mannuronic (M) alginate, but a prolonged period of 
growth suppression was observed if the alginate was of high guluronic (G) acid content 
[71].  Although freshly encapsulated βTC cells exhibit a secretion profile very similar to 
unencapsulated cells, it is unknown whether this remodeling process and growth 
inhibition would cause any changes in the insulin secretion profile, and we attempted to 
address this question in Chapter 3 of this thesis.  
 
2.4.5 Genetically engineered non-β cells 
Non-β cells can be taken as a biopsy from a patient and be genetically engineered ex 
vivo to become insulin-secreting cells.  Genetically modified cells with the proper 
insulin-secretion characteristics could then be directly implanted through engraftment or 
be associated with biomaterials in a construct, the latter having the advantage of 
retrievability if needed.  Since these cells are autologous and not β-cells, they relax the 
immune acceptance problems intrinsic to the use of xeno- or allogeneic cells as well as 
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the autoimmunity towards β cells in Type 1 diabetes.  Presumably, these cells have no 
supply limitations and can be cryo-preserved after genetic modification for subsequent 
needs.   
To be eligible as a potential replacement of daily insulin injections, β-cell surrogates 
must possess two important features:  the ability to process and produce mature insulin 
and to release insulin kinetically coupled with changes in blood glucose concentrations.  
In terms of producing mature insulin, because most non-β cells do not carry the two 
prohormone convertases PC1/3 and PC2, which cleave the proinsulin at the B-C junction 
after Arg-32 and the C-A junction after Arg-65, respectively, the two processing sites of 
the proinsulin molecule were converted by Yanagita to a consensus furin recognition site 
[72-74].  As furin is ubiquitously expressed in most cells, non-β cells such as 
hepatocyes, fibroblasts, and myoblasts that were transfected with the modified 
preproinsulin gene can produce functional insulin.  An additional mutation was later 
introduced to increase the stability of the insulin molecule by changing histidine B10 to 
aspartic acid [72].  The preproinsulin cDNA used in CHAPTERS 5, 6 is furin 
compatible with B10 mutation.  Another approach proposed by Lee et al [75] to equip 
cells with the ability to produce bioactive insulin was to construct a single-chain insulin 
analogue without the need of enzymatic processing.  However, the recombinant 
modified insulin has only 20-40% activity of human insulin, and there is the concern of 
possible physiological abnormalities caused by the lack of C-peptide [76].     
Although non-β cells now have the ability to produce and secrete mature insulin, the 
major obstacle lies in coupling the synthesis and release of recombinant insulin to 
glucose concentrations.  The following paragraphs discuss specific approaches taken 
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with different cell types as the insulin source and their rationale.  
 
2.4.5.1 Hepatocytes 
Liver is the first main organ that insulin reaches via the blood stream and is also the 
major site of insulin action; hence, the most popular cell type to be developed into a β 
surrogate is the hepatic cell.  Besides the above reasons, hepatocytes possess 
glucose-sensing ability because they express GLUT2 [77] and glucokinase [78], the two 
important glucose-sensing elements existing in β cells.  Moreover, hepatocytes not only 
regulate the expression of various proteins but also express some genes under 
glucose-responsive transcriptional control that can be utilized to regulate insulin secretion. 
Examples described below are the promoters for phosphoenolpyruvate carboxykinase 
(PEPCK), Glucose-6-phosphatase (G6Pase), and L-type pyruvate kinase (L-PK).      
The phosphoenolpyruvate carboxykinase (PEPCK) promoter is regulated in a 
complex manner by insulin, glucagon, and glucose.  Insulin expression under the control 
of PEPCK is up-regulated by glucagon (via cAMP) and glucocorticoid and down- 
regulated by insulin [79].  Nonetheless, there exists evidence that the promoter might be 
suppressed by glucose independently of insulin, hence, this promoter might not be ideal 
for clinical application [80, 81].  G6Pase gene promoter is stimulated by glucose and 
suppressed by insulin [6].  This promoter is relatively weak and was modified to 
enhance its activity by incorporating the liver specific aldolase B enhancer in the 
promoter region.  Adenoviral delivery of insulin gene under the regulation of modified 
G6Pase promoter into STZ-induced diabetic rats has shown some promising results, but 
the glucose-challenge tests indicated sluggish kinetics of insulin release [82].  
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The L-PK promoter is the regulatory element in controlling the expression of the 
liver-type pyruvate kinase gene in response to glucose.  However, the promoter was 
believed to be relatively weak and unlikely to induce efficient transgene expression.  
Nonetheless, Lee et al [75] demonstrated that when the L-PK promoter was used to 
express a single-chain insulin analog (SIA) with an SV40 enhancer to elevate the basal 
levels of SIA expression, in the setting of recombinant adeno-associated virus (rAAV) 
that were later injected into the portal vein, there was sufficient insulin to restore 
normoglycemia in diabetic rodents.  Secretion of SIA from hepatocytes was indeed 
glucose-dependent, but glucose-tolerance tests showed there was a 3-4 hour delay of SIA 
peak level after administration of glucose and 6 hours at minimum for SIA to return to 
basal level after removal of glucose.  Thule et al [83, 84] connected the 
glucose-responsive element (GIRE) from the L-PK promoter into the liver-specific, 
insulin-suppressive basal promoter elements from the insulin-like growth factor binding 
protein-1 (IGFBP-1).  Insulin secretion from this cassette was glucose up-regulated and 
insulin down-regulated.  Using adenovirus as the delivery vehicle by injection into the 
portal system of spontaneously diabetic BB/Wor rats, the transgene restored 
normoglycemia up to 12 weeks [85].  
Although utilizing glucose-responsive promoters enables the hepatic cells to release 
insulin in response to glucose concentrations, the kinetics of insulin release from these 
cells are slow compared to the rapid insulin release from the β cells.  This is largely due 
to the fact that hepatocytes do not carry secretory granules and insulin secretion is 
regulated only at the transcriptional level.  Even if transcriptional responses can be 
improved, pre-existing mRNA can result in continued production of insulin.  
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Consequently, the sluggishness of insulin secretion might result in the patient 
experiencing a period of hyperglycemia prior to transcriptional activation and secretion of 
insulin; and a period of hypoglycemia before the glucose-responsive promoter is 
down-regulated and all the insulin mRNA degraded.  To expedite the degradation of 
mRNA thus improving the down-regulation kinetics, Tang and Sambanis [86] engineered 
the preproinsulin mRNA so as to destabilize it through nonsense-mediated mRNA decay 
(NMD).  The engineered preproinsulin mRNA carried three insulin gene copies with 
stop codons in the middle of the mRNA molecule to induce NMD.  The level of the 
engineered preproinsulin mRNA expressed under transcriptional regulation in human 
hepatomas declined faster upon switching off transcription than that of the one-copy 
non-engineered control.  This methodology is expected to be generic and applicable to 
different host cells, including primary cells.  
 
2.4.5.2 Myoblasts 
Myoblasts is another attractive cell choice for insulin as well as other therapeutic 
protein delivery.  Because skeletal muscle constitutes a high percentage (40%) of body 
weight of an average individual [87], myoblasts are abundant and easily accessible.  
When growing in vitro, myoblasts are dividing rapidly and can be genetically engineered 
to secrete high amounts of recombinant proteins.  These cells also have the potential of 
differentiating into non-dividing myotubes, which can survive for long periods of time in 
vivo if properly implanted.  Types of therapeutic protein that have been expressed in 
myoblasts include: ciliary neurotrophic factor (for neurodegenerative disease) [88], 
erythropoietin (for chronic renal failure, cancer or AIDS-associated anemia) [89], factor 
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IX (for haemophilia B) [90, 91], factor VIII (for haemophilia A) [92], growth hormone 
(for skeletal muscle wasting) [93], and vascular endothelial growth factor (for promoting 
localized angiogenesis) [94].  
Genetically modified myoblasts can be injected into muscle tissue for therapeutic 
use, however, this approach faces some drawbacks.  One is the decrease of cell viability 
observed to occur few days after injection.  A second is that the long-term survival of 
the implant depends on the rare fusion events with host muscle cells.  A third is the 
concern of retrieveability if needed.  Hence, it appears necessary to associate myoblasts 
with biomaterials prior to implantation.  One of the promising approaches proposed by 
Aebischer et al [88, 89] is to encapsulate myoblasts in polyethersulfone hollow fibers and 
later induce myoblast differentiation by culturing the fibers in differentiation media prior 
to implantation.  Another approached proposed by Vandenburgh et al [93] is to 
tissue-engineered myoblasts into a bioartifical muscle (BAM).  BAM was developed by 
suspending proliferating myoblasts in an ECM gel and then casting the mixture into 
silicon rubber molds containing end attachment structures (artificial tendons).  After the 
gel solidified and dehydrated, the resulting cylindrical structure caused the differentiating 
muscle fibers to organize into parallel bundles.  Although the morphologic features of 
the BAM are significantly different from those of in vivo skeletal muscle, BAM has the 
advantages of retrieveability and long-term usage as a living protein delivery device.  In 
contrast to the approaches mentioned above, myoblasts encapsulated inside alginate do 
not proliferate as well and the ability of differentiation seems to decrease [95].    
In terms of insulin delivery, when modified preproinsulin cDNA that is furin 
compatible was transfected into myoblasts, both undifferentiated myoblasts and 
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differentiated myotubes can process proinsulin into active human insulin with high 
efficiency and high secretion rate [7, 96].  However, because these cells lack a regulated 
secretory pathway as well as the glucose sensing elements, the insulin secretion 
characteristic will never meet the clinical requirements.  Due to the advantage of a 
living protein delivery device mentioned above, researchers now suggest to use 
engineered myoblasts in providing basal insulin levels along with fast–acting insulin 
preparations to cover meals. 
 
2.4.4.3 Fibroblasts 
Fibroblasts have the same advantages and disadvantages as myoblasts in developing 
insulin-secreting cells for IDD treatment.  Instead of regulating insulin release at the 
transcription level, Rivera et al [97] proposed a novel approach, in which they used a 
human fibrosarcoma cell line HT1080 as the model, to regulate insulin secretion in the 
endoplasmic reticulum (ER).  In their system, furin-compatible proinsulin was 
expressed as a fusion protein with a conditional aggregation domain that interacted with 
itself in a ligand-reversible manner.  In the absence of the ligand, aggregates of 
proinsulin were too large to depart the ER and were retained within the organelle.  
When the cells were exposed to a cell-permeant ligand, FKBP12, aggregates of 
proinsulin dissolved, the aggregation domain and C-peptide were removed by furin in the 
trans-Golgi apparatus, and insulin was released from the cells.  The kinetics of insulin 
release were relatively fast compared to transcriptionally regulated cells, the highest 
insulin-secretion rate was observed 30 minutes after drug administration, and the rate 
declined to 10 to 20% of peak level 2 hours after the removal of the stimulus.  When 
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cells expressing proinsulin fusion protein were implanted into STZ diabetic mice, 
intravenous administration of the ligand into the animal helped to bring down the blood 
glucose within 2 hours.  The major drawback of this approach is that the release of 
insulin was not regulated by glucose but by a synthetic drug that might be harmful to the 
patient after long-term use, and it is unclear whether accumulation of protein inside the 
ER would cause some toxic effects to the cells.  Nonetheless, this approach indeed 
successfully demonstrated the possibility of regulating insulin release at the 
post-translation level within the cells.      
 
2.4.4.4 Non-β Endocrine Cells 
Since the main reason that genetically-engineered nonendocrine cells such as 
hepatocytes, myoblasts, and fibroblasts, can not exhibit proper secretion profile is 
because they lack the secretory pathway to secrete insulin in response to glucose, it is 
reasonable to think that using cells expressing a regulated secretory pathway might solve 
the problem.  The AtT-20 cell line, derived from an anterior mouse pituitary tumor, is 
the first neuroendocrine cell being engineered to become β surrogate because it contains 
both the constitutive and regulated secretory pathways, has enzymes to process proinuslin 
into insulin, and expresses glucokinase (but not GLUT 2) [98] so it might be able to 
exhibit glucose-responsive secretion.  Studies have shown that overexpression of 
GLUT2 and glucokinase enabled insulin-secreting AtT-20 to release insulin in response 
to glucose, however, with a maximal rate at the subphysiological glucose concentration 
of 10 µM [99], and in addition, the manipulation resulted in glucose-induced toxicity and 
severe apoptosis in these cells [100].  Another concern of using this cell type is that they 
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also have high production of endogenous adrenocorticotropic hormone (ACTH), which 
would upset the hormonal balance of the patient and cause serious disease (Cushing’s 
syndrome).  Futhermore, it might be difficult to obtain and transfect the autologous 
pituitary cells.   
The secretion kinetics of incretin hormones, glucagons-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP), from two intestinal enteroendorcine 
cells, L-cells and K cells, are very similar to those of insulin from β cells following 
glucose ingestion by normal human subjects [101].  Based on this unique property, 
Cheung et al [102] expressed proinsulin in transgenic mice under control of the GIP 
promoter.  The results showed that the transgene expressed specifically in K cells of 
duodenum and stomach, and after the destruction of β cells, STZ diabetic mice were able 
to regulate glycemia and exhibit a proper response to glucose tolerance test.  Tang and 
Sambanis [103] genetically engineered a human intestinal enteroendocrine L-cell model, 
the NCI-716 cell, by recombinant adeno-associated virus serotype 2 (rAAV2), and 
showed that the differentiated L cells released recombinant insulin simultaneously with 
endogeneous GLP-1 upon stimulation.  This research has opened significant avenues for 
cell-based therapy in treating insulin-dependent diabetes, but clearly more studies need to 
be done, including translating this approach from transgenic embryos to adult animals.  
 
2.5 Cell-material hybrid constructs 
As discussed above, while various glucose-responsive materials have been 
developed and different cell types have been genetically engineered for regulated insulin 
release, the two have not yet been combined in a hybrid construct.  In such a device, 
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cells can act as continuous insulin secretor and the material can act as a control barrier for 
insulin released by the cells.  The concept and proposed prototype are addressed in this 
thesis. 
 
2.6 Objective of the thesis 
As discussed above, a major concern in selecting a proper cell source for developing 
a tissue engineered pancreatic substitute is the secretion properties of the cells.  Thus, 
the overall objective of this thesis is to characterize and improve the secretion properties 
of tissue engineered pancreatic substitutes based on genetically engineered cells, and the 
specific aims are: (1) to characterize the effects of cell remodeling process on the 
secretion properties of the encapsulated insulinoma cells (CHAPTER 3);  (2) to develop 
a new methodology for improving the secretion properties of genetically engineered 
non-β cells, namely, using a glucose-responsive material based on con A to control the 
release of insulin secreted by the cells (CHAPTERS 4 and 5);  (3) to improve the 
glucose sensitivity of the con A-based material so that it responds to physiologically 
relevant glucose concentrations (CHAPTER 6).  Conclusions and future directions for 
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In developing a pancreatic substitute for the treatment of insulin-dependent diabetes, 
a major constraint is the limited availability of normal pancreatic islets.  This constraint 
can be relaxed by using genetically engineered continuous β cell lines, which grow easily 
in culture and also possess some of the insulin secretion characteristics exhibited by 
normal β cells.  To improve their immune acceptance, cells can be encapsulated in 
alginate/ poly-L-lysine/ alginate (APA) beads without loss of secretory capacity. However, 
as a result of cell growth and death, there is remodeling in the capsules, and this may 
change the secretory dynamics of the encapsulated cell system.  In this study, we 
cultured mouse βTC3 insulinomas in APA beads made of high guluronic (G) or high 
mannuoric (M) alginate, and conditionally transformed mouse βTC-tet insulinomas in 
high M alginate beads in the absence of tetracycline or in the presence of the antibiotic to 
suppress cell growth.  The secretion dynamics of the preparations were characterized at 
various time points by loading beads in a single-pass perfusion system and performing 
step changes in the concentration of glucose in the perfusion medium.  Secretory 
profiles were compared against free cell controls and free porcine pancreatic islets.  
Results indicated that the insulin secretion profile changes as the beads remodel with time 
in culture, however, the secretion profile can be retained if cell growth is suppressed.  
The implications of these findings regarding in vivo experiments with diabetic animal 
45 
models are discussed.  
 
3.2 Introduction  
The treatment of type 1 insulin-dependent diabetes by transplantation of allogeneic 
pancreatic islets is receiving increased attention following the success of the Edmonton 
protocol [107].  However, a major limitation of this approach is the shortage of human 
islets from cadaveric donors.  Additionally, the steroid-free immunosuppression used, 
although more benign than conventional regimens based on cyclosporine, still results in 
long-term complications [108, 109]. 
To overcome these problems, cell sources alternative to human islets and methods to 
reduce the necessary immunosuppression are being sought.  For the latter, encapsulation 
in permselective membranes is commonly employed to provide partial immune 
protection of an implant from the host.  Cells from a different species, e.g., porcine islets, 
are theoretically amply available.  However, there exist significant technical challenges 
associated with their large-scale isolation under the required conditions of purity and 
sterility, and concerns about the possible transmission of pathogens to humans remain 
[56].  Furthermore, survival and function of xenografts in non-immunocompromised 
hosts is particularly difficult to accomplish even with encapsulation [57, 110, 111].  The 
family of βTC insulinomas developed in transgenic mice by Efrat and co-workers 
constitutes an important development towards solving the cell availability problem [67, 
70].  These cells are easy to amplify in culture, they have a high insulin secretion rate 
relative to other continuous β cell lines or genetically engineered non-β cells, and they 
retain many important insulin secretion characteristics of normal β cells.  The βTC-tet 
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cells in particular, in which expression of the SV40 T antigen (Tag) oncoprotein is tightly 
and reversibly regulated by tetracycline, proliferate when Tag is expressed in the absence 
of tetracycline and stop proliferating in the presence of tetracycline that shuts off Tag 
expression [70, 112].  Such reversible transformation is an elegant approach in 
generating a supply of β cells via proliferation of an inoculum, followed by arrest of cell 
growth when the desirable population size is reached.  Although human cell lines 
similar to βTC are not currently available, they may be developed in the future.  
Furthermore, encapsulated βTC lines constitute an important model of a pancreatic 
substitute for studies in vitro and in diabetic animal models in vivo. 
As the βTC3 and, in the absence of tetracycline, the βTC-tet are proliferative cell 
lines, the cells continue to grow post-encapsulation.  The growth pattern exhibited in the 
commonly used calcium alginate/ poly-L-lysine/ alginate (APA) beads depends on the 
alginate composition [113-115] and is also influenced by oxygen availability [116].  For 
instance, βTC3 cells in APA beads experience prolonged growth suppression if the 
alginate is of high guluronic (G) acid content, whereas no significant growth suppression 
occurs in beads made of high mannuronic (M) alginate.  Following growth-mediated 
remodeling, the cells form clusters, which are distributed differently in high G and high 
M-based beads.  Although APA-encapsulated βTC cells retain for prolonged periods of 
time their capacity to secrete insulin, the precise dynamics of insulin secretion upon 
glucose up and down-regulation and the effect of growth-mediated remodeling on 
secretion dynamics remain unknown.  Insulin secretion dynamics are important at 
restoring normoglycemia in vivo, especially in higher animal models. 
In this study, βTC3 and βTC-tet mouse insulinoma cells were encapsulated in APA 
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beads of different alginate compositions and propagated for prolonged periods of time.  
The insulin secretory profiles in response to glucose concentration step changes were 
evaluated at different time points using a single-pass perfusion system.  The effect of 
tetracycline on the secretory profile of encapsulated βTC-tet cells was also characterized.  
Results were compared against those of free βTC cells, free porcine, and one preparation 
of free human pancreatic islets.  The implications of these studies to in vivo experiments 
are discussed. 
 
3.3 Materials & Methods 
3.3.1 Cells and cell culture 
βTC3 [67] and βTC-tet [70] cells were obtained from the laboratory of Shimon Efrat, 
Albert Einstein College of Medicine, Bronx, NY.  Cells of passage number 42-45 (βTC3) 
and 33-37 (βTC-tet) were used in this study.  Cells were cultured as monolayers in 
T-flasks with culture medium changed every 2-3 days. Culture medium consisted of 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Chemical Co., St. Louis MO) 
with 25 mM glucose, supplemented with 15% horse serum (from Hyclone (Logan, UT) 
and Sigma for βTC3 cells and βTC-tet cells respectively), 2.5% bovine serum (Mediatech, 
Herndon, VA), 1% penicillin-streptomycin (Mediatech) and L-glutamine (Gibco, Grand 
Island, NY) to a final concentration of 6 mM.  Upon reaching 100% confluence, cells 
were harvested by trypsin-EDTA (Sigma) for encapsulation.   
Porcine islets were isolated in Dr. Hering’s lab at the University of Minnesota. Islets 
were cultured overnight, then shipped by overnight express mail to Drs. Weber and 
Safley at Emory University, Atlanta, Georgia.  Upon arrival in Atlanta, a fraction of the 
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islets were transferred to Georgia Tech for immediate initiation of a perfusion experiment.  
Thus, perfusion experiments were performed 2 days after islet isolation.  Human islets 
were isolated a day prior to the perfusion experiment from a cadaver by the Emory 
University Juvenile Diabetes Research Foundation International Center for Islet 
Transplantation.    
 
3.3.2 Cell encapsulation 
Cells were encapsulated at a density of 3x107 cells/ml alginate using an electrostatic 
droplet generator (Nisco Engineering Inc., Zurich, Switzerland) and following the 
procedure of Stabler et al [114] for preparation of alginate-poly-L-lysine-alginate beads.  
Low molecular weight, high guluronic acid content alginate (LVG: 73% guluronic 
content) or low molecular weight, high mannuronic acid content alginate (LVM: 38% 
guluronic content) (Pronova, Norway) were used for βTC3 cells; high mannuronic acid 
content alginate (40% guluronic content) (ISP Inc., San Diego, CA ) was used for βTC-tet 
cells.  The final bead size was 700-800 µm in diameter.  Bead aliquots of 
approximately 2 ml volume were cultured with 40 ml of culture medium in each of five 
T-75 flasks placed on an orbital shaker within a humidified 37°C, 5% CO2/95% air 
incubator.  The spent medium was completely replaced with the fresh medium every 
two to three days at the beginning of the experiment and every one to two days towards 
the end as cells grew.  For the encapsulated βTC-tet cells, beads were propagated 
without tetracycline for 20 days, at which point the culture was split in two:  one-half 
continued to be propagated in the absence of tetracycline, and the other half was 
propagated in the presence of 30 ng/ml tetracycline (Sigma) up to day 30.  For all 
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entrapments, one of the T-75 flasks was used to withdraw samples of beads for perfusion 
and histology examination, while the others were used for glucose concentration 
measurements.  Three independent (n=3) bead preparations were performed for each 
type of culture studied (βTC3 cells in LVG, βTC3 cells in LVM, and βTC-tet cells in M 
alginate). 
 
3.3.3 Perfusion system and experiments 
The configuration of the perfusion system is shown in Figure 3.1.  A 
spindle-shaped glass tube of approximately 0.34 ml volume was used as the cell chamber.  
Cotton was placed at both ends of the chamber to retain the cells, free or encapsulated.  
A peristaltic cassette pump (Manostat, New York, NY) was used to generate the required 
flow rate; a multiport valve positioned before the cell chamber was used to control the 
type of medium flowing through the bed.  The whole apparatus except for the fraction 
collector was placed within a humidified 37°C, 5% CO2/95% air incubator.  Effluent 
samples were stored at -20oC for later assay of insulin.    The flow properties were 
evaluated by flowing through a cell-free system a square wave of FITC-insulin (Sigma) 
in PBS and assaying the FITC-insulin in effluent samples.  
With free βTC3 and βTC-tet cells, freshly trypsinized cells were counted by trypan 
blue (Sigma).  A total of 6x106 cells were mixed with macroporous cellulose (Sigma) 
and gradually loaded into the cell chamber.  With encapsulated βTC3 and βTC-tet cells, 
approximately the same number of cells, corresponding to 0.2 mL of alginate beads, was 
loaded in the perfusion chamber without any cellulose.  Cells were perfused at a flow 
rate of 0.25±10% ml/min, which ensured differential operation of the bed and measurable 
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insulin concentrations in the effluent samples.  Each experiment started by flowing 
culture medium for 30 minutes to allow for cell recovery from the loading process. Basal 
medium consisting of glucose-free DMEM without glutamine (Sigma) was then flowed 
through the bed for 1 hour to bring cells to their basal secretion level.  A glucose square 
wave of 1.5 hours high glucose was then implemented followed by 1.5 hours of basal 
medium.  The high glucose medium consisted of DMEM without glutamine and with 8 
mM glucose for βTC3 or with 20 mM glucose for βTC-tet cells.  For βTC-tet cells 
propagated in the presence of tetracycline, all perfusion media were supplemented with 
30 ng/ml tetracycline. 
With porcine or human islets, approximately 1000 IEQ were mixed with cellulose 
and loaded into the perfusion chamber.  The perfusion medium used for 30 min of islet 
conditioning consisted of E199 (Mediatech, Inc., Herndon, Virginia) containing 5.5 mM 
glucose and supplemented with 10% heat-inactivated porcine serum, 100 IU/ml penicillin, 
100 µg/ml streptomycin, 2 mM L-glutamine, 0.2% ciprofloxacin.  RPMI medium 
(Sigma) supplemented with BSA (Sigma), HEPES (Sigma), and glucose at concentrations 

















Figure 3.1 Single-pass perfusion system for measuring the secretion dynamics of free and 
encapsulated cells subjected to step changes in glucose concentration.  Free cells were 
mixed with macroporous cellulose and then gradually loaded into the cell chamber.  
Both free and encapsulated cells were retained in place with cotton plugs positioned 
upstream and downstream of the bed.  Step changes in glucose concentration were 
implemented by switching from one medium to the other using a multiport valve.  
Effluent samples were collected in a fraction collector for subsequent assay of secreted 
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FITC-insulin concentrations were measured by a fluorescence plate reader (Spectra 
Max Gemini Plate Reader, Molecular Devices Corp., Sunnyvale, CA) using a standard 
curve constructed from known FITC-insulin concentrations.  Glucose concentrations 
were determined by Glucose Trinder assay (Diagnostic Inc, Oxford, CT).  Secreted 
insulin was assayed by a rat insulin radioimmunoassay (Linco Research, St. Charles, 
MO), in which the insulin antibody exhibited 100% cross-reactivity against mouse insulin 
(manufacturer’s data).  Numbers of βTC3 and βTC-tet cells were measured by mixing 
suspensions of trypsinized cells with the trypan blue (Sigma, St. Louis, MO) and 
counting cells on a hemocytometer.   
 
3.3.5 Histology 
For histology, beads were washed with 1.1% CaCl2 and fixed in 3 % glutaraldehyde 
(Sigma). After embedding in a paraffin block, beads were sectioned, and slides were 
stained with hematoxylin/eosin (H/E). 
 
3.4 Results 
3.4.1 Control experiments 
To evaluate the time lag introduced by the free volume between the multiport valve 
and the system outlet, and the extent of axial mixing, a cell-free cellulose bed was 
subjected to a square wave of FITC-insulin.  Figure 3.2 shows the profile of 
FITC-insulin at the output in response to the square wave at the input.  There was an 
approximately 4.5 min time lag for both step up and step down.  This compares well 
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with the calculated residence time t=V/Q of 4 minutes, where V= 1 ml is the volume 
between the valve and the system outlet, and Q=0.25 ml/min is the perfusion flow rate.  
The more gradual ascent and descent of FITC insulin at the output relative to the input 
was apparently the result of some axial dispersion.  The observed performance was 
adequate for evaluating the secretory characteristics of free and encapsulated cells with 


























Figure 3.2  Profile of FITC-insulin at the output of perfusion system in response to a 





3.4.2 Secretion from islets 
Figure 3.3 shows typical results from a perfusion experiment with porcine islets.  
Shortly after glucose stimulation, the insulin secretion rate reached its maximum.  By 30 
minutes post-stimulation, the insulin secretion rate had declined to approximately 50% of 
its highest value, and it continued to gradually decline for the rest of the induction period.  
One perfusion experiment was also performed with human islets (results not shown) and 
the secretion profile was similar to that shown in Fig. 3.  This type of secretion profile is 
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Figure 3.3 Dynamic secretory response of porcine islets subjected to a square wave of 
glucose concentration from 1.67 to 16.7 to 1.67 mM. 
 
 
3.4.3 Effects of alginate composition on secretion dynamics of encapsulated βTC3 
cells 
βTC3 cells encapsulated in LVG and LVM exhibited different growth and 
remodeling patterns, as illustrated by the rate of glucose consumption (GCR) and the 
histological observation of beads at different time points (Figure 3.4).  For LVM beads, 
cells overcame any growth inhibition quickly, and the GCR started to increase from day 4 
onward. Histology slides indicated that remodeling inside the LVM alginate was diffusion 
driven:  cells grew and formed clusters at the periphery of beads where oxygen was 
more available.  For LVG beads, there was a prolonged growth suppression of cells, 
with GCR being essentially constant for 20 days before starting to increase.  Cell growth 
resulted in clusters randomly dispersed throughout the beads.  When normalized to GCR, 
the rate of insulin secretion (ISR) in the T-flask cultures was lower at the end of the 
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long-term cultures for both types of alginate.  Specifically, the ISR/GCR ratio declined 
from 2.79±0.46 (mean ± std. dev.) µU/nmole on day 5 to 1.55±0.33 µU/nmole on day 19 
for the LVM culture, and from 3.16±0.14 µU/nmole on day 2 to 0.72±0.26 µU/nmole on 
day 38 for the LVG culture.  These trends are all consistent with trends reported by 
Stabler et al [114, 115].  
The secretion dynamics of freshly trypsinized βTC3 cells loaded with cellulose in 
the perfusion chamber are shown in Figure 3.5a.  Free cells responded essentially 
immediately to glucose stimulation, as indicated by the rapid increase in insulin secretion 
rate from the first sample taken after the system time lag.  The insulin secretion rate 
decreased to below 50% of its highest value after 30 minutes of glucose stimulation.  
Secretory responses of LVG-encapsulated cells are shown in the other panels of Figure 
3.5 and of LVM-encapsulated cells in Figure 3.6.  The encapsulation process did not 
affect the glucose-stimulated secretion dynamics, as freshly encapsulated cells in both 
LVM and LVG exhibited secretion profiles very similar to those of free cells (day 2 LVG:  
Figure 3.5b; day 3 LVM:  Figure 3.6a).  Perfusion results from beads propagated for a 
period of time, in particular LVG-encapsulated cells on day 38 (Figure 3.5d) and 
LVM-encapsulated cells on day 20 (Figure 3.6c), indicated that capsules retained their 
fast response to glucose stimulation, but a high rate of secretion was maintained longer 
under glucose stimulation relative to the free and freshly encapsulated cells.  
Specifically, the insulin release rate was maintained above 50% of its highest value after 
30 minutes of glucose stimulation.  Results from intermediate time points (LVG day 20, 
Figure 3.5c, and LVM day 13, Figure 3.6b) differed depending on the type of alginate.  
With high M beads, the secretion profile was comparable to freshly encapsulated beads, 
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whereas with high G beads, the profile was comparable to that of the final time point.  
With both types of alginate and at all time points, insulin secretion returned to its basal 
rate within 15 minutes after the glucose step down.   
The characteristics of the above secretion dynamics patterns are summarized in 
Table 3.1.  The percentage of induced insulin secreted during the first 25 minutes was 
calculated by dividing the amount secreted during the first 25 minutes post-induction by 
the total amount secreted during the 1.5 hours of glucose stimulation.  The glucose 
induction-fold reported in Table 3.1 was calculated by dividing the total amount of 
insulin secreted during the 1.5 hours of induction by the total amount of insulin secreted 
during the following 1.5 hours of exposure to glucose-free basal medium.  The 
sharpness of the secretory profile of free and freshly encapsulated in both LVG and LVM 
βTC3 cells is reflected by the higher values of the percentage of induced insulin secreted 
during the initial 25 min after the glucose step up.  Following long-term culture, the 
percentage of induced insulin secreted during first 25 minutes decreased, as the secretion 





















Figure 3.4 Temporal changes in the rates of metabolic activity (glucose consumption rate) 
for βTC3 cells encapsulated in 2% LVG (open squares) and 2% LVM (solid 
diamonds)-based APA beads.  Representative histology cross-sections of 
APA-encapsulated βTC3 cells are:  LVM beads at day 2 (left), LVM beads at day 20 
















































































































Figure 3.5 Dynamic secretory response of free βTC3 cells (a) and of 2% 
LVG-encapsulated βTC3 cells at day 2 (b), day 20 (c), and day 38 (d) subjected to a 










































































































Figure 3.5  Dynamic secretory response of free βTC3 cells (a) and of 2% 
LVG-encapsulated βTC3 cells at day 2 (b), day 20 (c), and day 38 (d) subjected to a 




































































































Figure 3.6  Dynamic secretory response of APA-encapsulated βTC3 cells in 2% 
LVM-based capsules at day 3 (a), day 13 (b), and day 20 (c) subjected to a square wave 




























































Figure 3.6  Dynamic secretory response of APA-encapsulated βTC3 cells in 2% 
LVM-based capsules at day 3 (a), day 13 (b), and day 20 (c) subjected to a square wave 
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3.4.4 Effects of growth suppression on secretion dynamics of encapsulated βTC-tet  
Cells 
 
Figure 3.7 shows the glucose consumption rate (GCR) and representative histology 
cross-sections of encapsulated βTC-tet cells as functions of time.  Encapsulated cells 
were propagated in tetracycline-free medium for 20 days, at which point the culture was 
split in two:  half the amount of beads continued to be propagated in the absence of 
tetracycline, whereas the other half was cultured in the presence of 30 ng/ml of the 
antibiotic.  The βTC-tet cells in ISP alginate exhibited a long lag before GCR started to 
increase.  In the absence of tetracycline, GCR started to increase around day 20, and by 
day 30 histology revealed a dense peripheral band of cells, indicating that the cell 
remodeling was also primarily driven by oxygen availability.  Beads propagated with 30 
ng/ml of tetracycline maintained the same glucose consumption rate, and histology at day 
30 revealed a pattern similar to that observed with day 20 beads.  These results are 
consistent with data from monolayer βTC-tet cell cultures which, when propagated with 
30 ng/ml tetracycline after reaching 80% confluency, also stopped proliferating over a 
period of 10 days (results not shown).  The time change of the (ISR/GCR) ratio of the 
encapsulated cells in the T-flask cultures depended on whether tetracycline was 
administered or not.  In the absence of tetracycline, (ISR/GCR) declined from 5.8±1.76 
µU/nmole on day 2 to 1.26±0.88 µU/nmole on day 30.  On the other hand, when 
tetracycline was administered from day 20 to day 30, the (ISR/GCR) ratio on day 30 was 
9.75±2.80 µU/nmole.   
As with βTC3 cells, the encapsulation process had no immediate effect on the 
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secretion profile of βTC-tet cells.  Beads cultured without tetracycline had a broader 
secretion profile at day 30 (Figure 3.8c) relative to day 20 beads (Figure 3.8a).  On the 
other hand, the secretion profile from beads propagated with tetracycline from day 20 
onward (Figure 3.8b) was very similar to the profile of day 20 beads, indicating that 
growth inhibition by tetracycline preserved the secretory profile.  The spikes observed 
after the step down in glucose concentration were probably due to the sensitivity of 
βTC-tet cells to the small pressure change during medium switches.  These spikes did 
not affect the overall secretory profile, including the sharpness of the response to the 
glucose step-up. 
The secretion characteristics of βTC-tet cells are also listed in Table 3.1.  Day 30 
beads cultured without tetracycline had different secretion characteristics compared to 
day 20 beads, in that both the percentage of induced insulin secreted during the first 25 
minutes and the induction-fold decreased.  On the other hand, there were no statistical 
differences in these two parameters between day 20 and day 30 beads, when the latter 




























Figure 3.7 Temporal changes in the rates of metabolic activity (glucose consumption rate) 
for βTC-tet cells encapsulated in 2% alginate. Representative histology cross-sections of 
alginate encapsulated βTC-tet cells are (from left to right): day 2, day 20, and day 30 












































































































Figure 3.8 Dynamic secretory response of 2% APA-encapsulated βTC-tet cells at day 20 
(a), and day 30 of beads propagated with (b) and without (c) 30 ng/ml tetracycline 
between day 20 and day 30 and subjected to a square wave of glucose concentration from 








Figure 3.8 (continued). 
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Figure 3.8  Dynamic secretory response of 2% APA-encapsulated βTC-tet cells at day 
20 (a), and day 30 of beads propagated with (b) and without (c) 30 ng/ml tetracycline 
between day 20 and day 30 and subjected to a square wave of glucose concentration from 





In a cell-based therapy for insulin-dependent diabetes, the cells used should, 
ideally, exhibit the same insulin secretion dynamics as normal islets.  Thus, the secretion 
of insulin should be glucose-dependent and exhibit fast kinetics in response to glucose 
and other physiologic stimuli.  Static incubation of islets in media containing different 
glucose concentrations can elucidate the dependence of insulin secretion on glucose 
concentration.  However, to capture the dynamic response of insulin release, a single 
pass perfusion system is more appropriate.  Following a step up in glucose concentration, 
islets exhibit a biphasic insulin secretion profile.  The initial acute phase of insulin 
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release is due to the discharge of insulin stored in readily releasable granules, whereas the 
second more prolonged phase of insulin secretion is attributed to elevated insulin 
biosynthesis and/or to the preparation of another group of granules for release [52, 53]. 
The biphasic insulin secretion pattern of islets has been reported to differ among 
different species [118].  Perfusion results with isolated mouse islets exhibited a sharp 
first phase of secretion, with the second phase of insulin release being at a flat and much 
lower rate than the maximum rate of the first secretion phase.  In contrast, perfusion 
results with isolated rat islets indicated that the insulin secretion rate during the second 
phase was comparable to the maximum rate of the first phase.  This difference has been 
attributed to different forms of cyclic AMP or the expression of distinct isoforms of 
protein kinase C in β cells of different species [119, 120].  However, it should be noted 
that differences in islet secretion profiles can be attributed not only to intrinsic 
biochemical differences but also to subtle differences in perfusion conditions.  For 
instance, when isolated human islets were perfused in vitro, the insulin secretion profile 
was reportedly similar to the biphasic response of mouse islets [117, 121] and also 
resembled the secretion profile obtained in this study with porcine islets (Figure 3.3).  
On the other hand, when secretion from human islets was studied in vivo by the 
hyperglycemic clamp technique, in which the plasma glucose of a human test subject was 
subjected to a step increase and sustained at 10 mM for two hours by controlled glucose 
infusion, the secretion profile resembled that reported for rat islets [122, 123].  Free 
βTC3 and βTC-tet cells exhibited secretion profiles similar to those obtained porcine 
(Figure 3.3) and human islets in this study and reported in vitro with mouse and human 
islets elsewhere [117, 121]:  an acute first phase of insulin secretion was followed by a 
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second lower and flat or slowly declining second phase of insulin secretion.   
The similarity in secretion profiles of free and freshly encapsulated insulinomas 
indicated that the encapsulation process did not affect significantly the secretory cell 
function.  Although the remodeling pattern was different for βTC3 cells in LVM and 
LVG APA beads, the changes in secretion profiles with time were similar for both types 
of alginate following recovery from growth suppression.  After prolonged culture, the 
secretion profiles became broader, as indicated by the decrease of percentage of induced 
insulin secreted during the first 25 minutes after glucose stimulation, and the induction 
fold also decreased.  Furthermore, when the insulin secretion rate was normalized to the 
glucose consumption rate, both measured in the T-flask cultures, the normalized insulin 
secretion rate declined with time in culture, possibly indicating a reduction in the overall 
secretory capacity of cells after prolonged propagation in APA beads. 
There are several possible causes of the changes in insulin secretion profile 
exhibited by APA-encapsulated insulinomas with time in culture.  One relates to 
changes in the cellular microenvironment.  Shortly after encapsulation, cells were 
homogenously distributed as single units inside the beads.  During the remodeling 
process, cells formed clusters and possibly deposited extracellular matrix [124], thus 
altering the cell-cell and cell-matrix interactions from those in freshly encapsulated 
preparations.  Furthermore, the rates of transport of oxygen and other nutrients and 
metabolites inside the cell clusters are expected to be lower than the transport rates in the 
alginate gel [125], resulting in a broader distribution of the nutritive microenvironments 
experienced by cells after remodeling vs. initially.  With the bead diameter and cell 
density used in this study, all encapsulated βTC3 cells were initially exposed to oxygen 
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concentrations above those limiting secretion [126].  However, after remodeling, it is 
likely that cells at the core of the clusters secreted insulin at reduced rates or not at all due 
to severe hypoxia at these locales.  Identifying the exact cause of the secretory profile 
changes with time would be interesting and significant, but such an investigation was 
clearly beyond the scope of this study. 
Previous studies [116] clearly indicate that encapsulated proliferative cells do not 
exhibit unlimited growth in capsules.  Instead, there is growth to the number of viable 
cells supported by the oxygen concentration in the environment.  At this point, the 
number of viable cells is maintained constant through equilibration of the rates of cell 
growth and death.  Thus, growth arrest of the type that can be implemented with 
βTC-tet cells may not be necessary for providing an upper limit to the rate of insulin 
secretion exhibited by encapsulated cells; rather, it appears necessary for decelerating or 
arresting remodeling and inhibiting accumulation of dead cells in capsules, possibly also 
for inhibiting the growth of any cells released from broken capsules.  As found in this 
study, the secretion profile of APA-encapsulated βTC-tet propagated in the absence of 
tetracycline, in which cells continued to grow and remodel, became broader from day 20 
to day 30.  On the other hand, with beads propagated in the presence of tetracycline, the 
secretion profile was preserved and the induction-fold was maintained at the same value. 
Thus, growth inhibition appears necessary for preserving the insulin secretion profile 
exhibited by an encapsulated cell system.  Moreover, as indicated by  the increase of 
the ISR/GCR ratio in encapsulated βTC-tet cells cultured in the presence of tetracycline, 
which in accord with previous findings with βTC-tet monolayers [127]:  growth arrest 
may stimulate expression of the insulin gene and of genes encoding components of 
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insulin secretory vesicles.  It should be noted that for encapsulated βTC-tet cells, both 
the concentration of tetracycline and the time of administration are critical in achieving 
growth arrest [128].  Thus, the in vivo implementation of this growth control 
mechanism may be challenging. 
It remains unclear whether the changes in insulin secretion dynamics exhibited by 
proliferating encapsulated insulinomas would change their effectiveness in providing in 
vivo glycemic control.  Such differences in effectiveness would be better manifested in 
large animal models, which have more elaborate glucose homeostasis relative to rodents.  
Besides characterizing the dynamic secretory changes occurring with time, this study 
clearly demonstrated that the method to maintain the secretory profile constant is growth 
suppression of the cells.  Growth arrest, either through regulation of expression of the 
SV40 T antigen (Tag) oncoprotein by tetracycline, as in the βTC-tet cells, or through 
some other mechanism, could potentially be applied in vivo if changes in secretory profile 
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Insulin-dependent diabetes is a serious pathological condition, currently treated by 
blood glucose monitoring and daily insulin injections, which, however, do not prevent 
long-term complications.  A tissue engineered pancreatic substitute has the potential to 
provide a more physiologic, less invasive, and potentially less costly treatment of the 
disease.  A major issue in developing such a substitute is the cells being used.  
Non-pancreatic cells, retrieved from the same patient and genetically engineered to 
secrete insulin constitutively or with some glucose responsiveness, offer the significant 
advantages of being immune acceptable and relaxing the tissue availability limitations 
which exist with islets from cadaveric donors.  These cells, however, do not exhibit 
insulin secretion dynamics appropriate for restoration of euglycemia in higher animals 
and, eventually, humans.  In this study, we present the concept of a hybrid pancreatic 
substitute consisting of such cells sequestered in a material exhibiting glucose-dependent 
changes of its permeability to insulin.  A concanavalin A-glycogen material sandwiched 
between two polycarbonate membranes and exhibiting glucose-dependent sol-gel 
transformations was used.  Rates of insulin transport through this material in gel and sol 
forms were characterized for both FITC-labeled insulin in solution and insulin secreted 
by βTC3 mouse insulinoma cells.  Effective diffusivities through sol were found to be 
up to 3.5-fold higher than through the gel state of the material.  A mathematical model 
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of a hybrid construct was formulated and analyzed to simulate the secretory behavior in 
response to step ups and downs in the surrounding glucose concentration.  The 
experimental and modeling studies indicate that a hybrid pancreatic substitute consisting 
of constitutively secreting cells and glucose-responsive material has the potential to 
provide a more physiologic regulation of insulin release than the cells by themselves or in 
an inert material. 
 
4.2 Introduction 
Insulin dependent diabetes (IDD) is a serious pathological condition affecting 
more than 4 million people in the United States with a total estimated annual cost of more 
than $80 billion.  The current treatment for this disease involves daily monitoring of 
blood glucose levels and multiple daily insulin injections.  This provides some control 
of the diabetic state, which, however, is far from the physiologic regulation achieved by a 
normally functioning pancreas and results in long-term complications, including 
cardiovascular disease, nephropathy, cataracts, retinopathy and skin ulcers.  A 
tissue-engineered pancreatic substitute consisting of insulin-secreting cells and 
biomaterials in a functional three-dimensional architecture has the potential to provide a 
more physiologic, less invasive, and potentially less costly treatment of the disease 
relative to insulin injections. 
A major issue in developing a pancreatic substitute is the cells being used.  A 
commonly studied configuration consists of pancreatic islets encapsulated in a 
permselective barrier for protection from the immune system of the host.  However, 
survival and function of these implants does not occur reproducibly and for a sufficiently 
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long period to encourage human clinical studies.  One possible cause of failure is that 
encapsulation provides only partial immune protection, since antigens released by 
implanted cells can pass through the membrane and cause immune activation of the host.   
Autologous cells constitute a promising alternative to pancreatic islets, since they 
are accepted immunologically.  Clearly, such cells have to be other than β pancreatic 
cells, since the latter have been destroyed or are seriously malfunctioning in 
insulin-dependent diabetics.  Genetic engineering of non-β cells for constitutive 
expression of recombinant insulin is straightforward, and indeed several investigators 
have expressed insulin in fibroblasts, myoblasts, and hepatocytes, among other cell types 
[129-131]. Glucose responsiveness may be introduced at the gene level by using 
promoters up-regulated by glucose and possibly down-regulated by insulin to drive 
proinsulin cDNA transcription [83, 84, 132].  However, such cells cannot exhibit the 
acute dynamics of insulin secretion, which are needed for normoglycemia in higher 
animals and, eventually, humans [133].   To address this problem, we hypothesized that, 
by sequestering cells in a material exhibiting glucose-dependent permeability changes 
with a short time-constant, one could physically re-create a glucose-responsive insulin 
storage compartment, which the cells are lacking biologically.  One such material is 
based on the lectin concanavalin A (con A) bound to the polysaccharide glycogen, which 
exhibits sol-gel transformations depending on the glucose concentration in the 
surrounding medium [134, 135].  This type of pancreatic substitute based on 
sub-optimally secreting cells sequestered in a glucose-responsive material constitutes a 
substantially different design from the encapsulated cell systems reported thus far, and 
poses a unique set of problems that need to be addressed prior to in vivo applications.   
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In this paper, we present this novel concept of the hybrid substitute consisting of cells and 
glucose-responsive material; we characterize the con A-glycogen complex as a 
glucose-sensitive barrier to insulin release from a solution or from a suspension of βTC3 
mouse insulinoma cells; and, to illustrate the insulin secretion profile that can be 
exhibited by this device, we develop and analyze a mathematical model of a hybrid 
device subjected to cycles of glucose concentration similar to those occurring 
physiologically.  The potential of this type of device for IDD treatment and areas where 
improvements are needed prior to in vivo studies are discussed. 
 
4.3 Materials and Methods 
4.3.1 Cells and cell culture 
βTC3 cells were obtaind from the laboratory of Shimon Efrat, Albert Einstein 
College of Medicine, Bronx, NY.  Cells of passage number 42-45 were used in this 
study.  Cells were cultured as monolayers in T-flasks with culture medium changed 
every 2-3 days. Culture medium consisted of Dulbecco’s Modified Eagle’s Medium 
(DMEM, Sigma Chemical Co., St. Louis MO) with 25 mM glucose, supplemented with 
15% horse serum (Sigma), 2.5% bovine serum (Mediatech, Herndon, VA), 1% 
penicillin-streptomycin (Mediatech) and L-glutamine (Gibco, Grand Island, NY)  to a 
final concentration of 6 mM.  Upon reaching 100% confluence, cells were harvested by 
trypsin-EDTA (Sigma) and encapsulated in 2% Keltone alginate (ISP Alginates Inc., San 
Diego, CA) at a density of 3x107 cells/ml alginate using an electrostatic droplet generator 
(Nisco Engineering Inc., Zurich, Switzerland) and following the procedure of Stabler et al. 
[71], except that the poly-L-lysine and final alginate layers were not added.    The final 
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bead size was 1 mm in diameter.  
4.3.2 Glucose-responsive material 
The con A-based material was prepared followed the general procedure of Tanna 
et al. [134, 136].  In initial experiments with dextran, the con A-dextran material proved to be 
less sensitive to glucose than the material with glycogen, hence glycogen was used in this study.  
Glycogen (type IX, G-0885), Concanavalin A (type V, C-7275), sodium m-periodate 
(NaIO4), and sodium borohydride (NaBH4) were all from Sigma.  In short, glycogen 
was first dissolved in PBS (pH=7.2) to form a concentrated solution of 60% w/v.  To 
activate the glycogen to the aldehydic form, NaIO4 was added and mixed with glycogen 
in the dark for 24 hr to final concentrations of 0.1 M and 30% w/v for NaIO4 and 
glycogen, respectively.  Following this, concanavalin A dissolved in PBS at 15% w/v 
was added to the activated glycogen at a 1:1 volume ratio.  Stirring of the mixture 
started immediately and continued until a viscous gel was formed.  The gel was left at 
room temperature for 24 hours, then a 1 mg/ml of NaBH4 solution was added at a 2:1 
volume ratio, and the material was immediately placed on a shaker at 4oC for 1 hr to 
stabilize the gel.  Finally, the gel was rinsed with PBS for at least 3 times and stored at 
4oC before use.  To test the phase changes of the material in different glucose 
concentrations, an amount of the material in PBS solution was loaded in a dialysis tube 
(12,000 MWCO, Sigma) and immersed in PBS, either glucose-free or containing glucose 
at 4% concentration.   
 
4.3.3 Diffusion experiments and assays 
 To measure the rate of insulin transport through the con A-glycogen material in 
the presence or absence of glucose, the two-compartment diffusion apparatus shown in 
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Figure 4.1 was used.  The compartments were separated by the con A-glycogen material 
sandwiched between two 0.1 µm pore size polycarbonate membranes (Osmonics Inc., 
Minnetonka, MN) positioned 2 mm apart by a silicon sheet.  The solutions in the donor 
and receiver compartments were mixed with a mixer or a stir bar to avoid boundary layer 
effects.  To load the material homogeneously, 0.5 ml of material was first transformed 
into sol by the addition of an equal volume of 10% glucose solution.  Following 
assembly of the entire diffusion apparatus, the material was injected into the space 
between the two membranes.  The sol was converted to gel in glucose-free PBS solution 
for 20 minutes prior to the beginning of diffusion experiments. 
 For experiments with insulin solutions, 1 mg/ml FITC-insulin (Sigma) in PBS 
was added to the donor compartment, whereas the receiver compartment was loaded with 
initially insulin-free PBS.  To convert a gel to sol, glucose was added to a final 
concentration of 4% in both compartments.  To convert a sol to gel, the solutions in both 
compartments were changed to glucose-free PBS.  Samples were taken every 15 
minutes, and FITC-insulin concentrations were measured by a fluorescence plate reader 
(Spectra Max Gemini Plate Reader, Molecular Devices Corp., Sunnyvale, CA) using a 
standard curve constructed on the basis of known FITC-insulin concentrations.  
Experiments with FITC-insulin were performed at room temperature. 
 To measure the amount of con A leakage during a gel-sol-gel cycle, the set up 
described above was used except that insulin-free PBS was loaded in both compartments. 
Samples from both compartments were assayed for total protein concentration by 
Coommassie Blue (Pierce, Rockford, IL). The amount of leakage was calculated based on 
assumption of no loss of con A during material preparations.  
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 In experiments with encapsulated βTC3 cells as the insulin source, 1.5 ml of 
alginate beads with cells were incubated in a T-25 flask in 5 ml of culture medium with 
20 mM glucose for 3 hours; during this time, secreted insulin accumulated in the medium.  
Beads and medium were then transferred to the donor compartment of the diffusion 
apparatus.  Fresh culture medium with 20 mM glucose was added to the receiver 
compartment and the entire apparatus was placed in a 37oC, 5%CO2 humidified incubator.  
Samples were taken every 30 minutes and frozen until assayed.  Insulin concentrations 
were measured by a double-antibody rat radioimmunoassay kit (Linco Research, St. 
Charles, MO), which exhibits a 100% cross-reactivity against mouse insulin 
(manufacturer’s data).  Cell viabilities were measured by dissolving the beads in 2.2% 
sodium citrate.  Cells were pelleted by centrifugation at 105 g for 3 min; pellets were 
re-suspended in fresh medium and cell viability was measured by adding trypan blue 
























Figure 4.1 Diffusion apparatus for measuring insulin transport rates through the con 
A-glycogen material in gel and sol states.  The material was sandwiched between two 
0.1 µm pore size polycarbonate membranes positioned 2 mm apart by silicon sheeting 
with a 2 cm diameter hole in the middle.  During preparation, the material was injected 
in sol state through the silicon sheeting to fill the space between the two membranes.  
The donor compartment, containing an insulin solution or insulin-secreting cells, had a 
volume of 6.5 mL.  The receiver compartment, in which the concentration of insulin 
transported through the material was measured, had a volume of 10 mL.  The area 




used to sandwich 
the silicon sheet 
and material 
Silicon sheet 





Receiver side, containing 
PBS or cell free medium  
Donor side, containing 
insulin solution or 
insulin-secreting cells  
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4.4 Results 
4.4.1 Experimental studies 
The chemical structure of the con A-glycogen material is illustrated schematically 
in Figure 2.10 and the macroscopic appearance of the gel and sol states in Figure 4.2.  In 
the latter figure, the material is in a dialysis tube of 12,000 molecular cut off to prevent 
leakage of con A and glycogen.  In glucose-free PBS solution, con A forms a 
three-dimensional gel matrix with glycogen.  When the glucose concentration is 
increased, glucose displaces con A from the matrix, the three-dimensional structure 
breaks down, and the gel becomes a sol.  When glucose is removed, the gel structure 
reforms.  We have been able to repeatedly transform the material in a dialysis tube from 
the gel to the sol state and vice versa by changing the glucose concentration between 0% 
and 4% (220 mM).  
The rates of insulin transport through the gel and sol states of the material were 
studied with the two-compartment apparatus illustrated in Figure 4.1.  Figures 4.3 and 
4.4 show results from typical experiments at room temperature with FITC-labeled insulin 
loaded in the donor compartment and assayed by fluorescent spectroscopy in the receiver 
compartment.  In the experiment of Figure 4.3, two diffusion chambers were run in 
parallel.  In apparatus 1, mass transfer of FITC-insulin was studied for 180 min with the 
material being always in the sol state.  In apparatus 2, the material was initially in the 
gel state; after 180 min, glucose was added to both compartments to a concentration of 
220 mM, converting the material to sol.  At 360 min, the solutions in both compartments 
were replaced with fresh glucose-free solutions; the solution in the receiver compartment 
was insulin-free and the solution in the donor compartment contained FITC-insulin.  
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Accumulation of FITC-insulin in the receiver compartment was in all cases measured as 
a function of time. 
Effective diffusivities Deff were calculated from the linear portions of the 
concentration profiles using equation (1) below and are reported in Figure 4.3.   
ln{[αCA0+ CB0-CB(1+α)]/[α(CA0-CB0)]}=-[(1+α)/α](ADeff/LVB)t   (1) 
(from [137]) 
where VA=volume of donor compartment; VB=volume of receiver compartment; α=VA/VB; 
CA=insulin concentration in donor compartment; CB=insulin concentration in receiver 
compartment; CA0, CB0=CA, CB, respectively, at time 0; L=thickness of material separating 
the two compartments; A=area through which insulin transport occurs; Deff=effective 
diffusivity.  The slopes of the concentration profiles indicate that the gel to sol 
transformation was completed in less than 40 min, whereas the sol to gel transformation 
occurred much slower and was not completed by the end of the experiment.  
Figure 4.4 shows results from a similar experiment, in which the sequence of 
material transformations in one of the apparati was in reverse order to that of Figure 4.3.  
In apparatus 1, mass transfer of FITC-insulin was studied for 180 min with the material 
being in the gel state.  In apparatus 2, the material was initially in the sol state; after 180 
min, the solutions in both compartments were replaced with fresh glucose-free solutions, 
with the solution in the receiver compartment being insulin-free and the solution in the 
donor compartment containing FITC-insulin.  At 360 min, glucose was added to both 
compartments of apparatus 2 to a concentration of 220 mM.  The accumulation of 
FITC-insulin in the receiver compartment was in all cases measured as a function of time, 
and effective diffusivities Deff were calculated from equation (1) above and are reported 
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in the figure. 
The average effective diffusivities of FITC-insulin, calculated for the material in 
the gel and sol states, are presented in Figure 4.5.  Data are expressed as the mean ± 
standard deviation. Statistical differences were evaluated by the Student’s t-test.  
Differences were considered significant at p<0.05.   
To assess the extent of material leakage through the polycarbonate membranes, 
following the experiments in Figures 4.3 and 4.4, the solutions in both chambers were 
changed to glucose-free PBS and the apparati were incubated overnight.  Some leakage 
of macromolecules was detected especially for the sol to gel to sol apparatus (Figure 4.4):  
the material recovered following the overnight incubation was of approximately 0.4 ml 
volume, whereas the material initially sandwiched between the two membranes had a 
volume of 0.5 ml.  Additionally, the concentration of leaked con A was measured by 
Coommassie Blue in an insulin-free apparatus.  It was found that approximately 10% of 
the initial con A amount leaked from the membrane sandwich by the end of a gel-sol-gel 
cycle. 
To illustrate that the glucose-responsive material can be combined with cells to 
create a hybrid device with improved secretion properties, the same diffusion apparatus 
was used, except that in this case the donor compartment contained mouse βTC3 
insulinomas.  To keep the cells in suspension without compromising their viability and 
functionality, the cells were encapsulated in 1 mm diameter, 2% calcium alginate beads at 
a density of 3x107 cells/ml alginate.  The diffusion apparatus was placed in a 37oC, 
5%CO2 humidified incubator.  Insulin secreted from βTC3 cells had accumulated in the 
donor compartment to approximately 150 ng/mL by the beginning of an experiment, and 
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it reached approximately 200 ng/mL by the experiment end.  These concentrations are 
much higher than those in the receiver compartment, which did not exceed 10 ng/mL.  It 
should be noted that unless the glucose concentration drops well below 1 mM, TC3  
cells are constitutive secretors of insulin [5].  This is because these cells overexpress the 
low Km glucose transporter GLUT1, as opposed to GLUT2, and hexokinase, as opposed 
to glucokinase, and consequently are hypersensitive to glucose [5, 68].  Thus, in the 
experiments of this study, the βTC3 cells were constitutive secretors of insulin.   
Figure 4.6 shows results from a typical experiment, in which the donor 
compartment contained alginate-entrapped βTC3 insulinomas, the receiver compartment 
was initially insulin-free, and the material was in the gel state.  At 180 min, glucose was 
added to the both compartments at a concentration of 220 mM transforming the material 
to sol.  Insulin that had accumulated in the donor compartment while the material was in 
the gel state was released when the material was converted to sol.  Calculated effective 
diffusivities are indicated in Figure 4.6. 
Figure 4.7 shows insulin effective diffusivities of the material from experiments 
with the diffusion apparatus containing βTC3 cells in the donor compartment.  Data 
were obtained with the material in the gel state for the duration of the experiment (bar A), 
the material in the gel state for the first 180 min (bar B) then converted to sol, and the 
material in the sol state following addition of 220 mM glucose at 180 min (bar C).  Data 
are expressed as mean ± standard deviation.  The higher effective diffusivities measured 
with βTC3 cells (Figure 4.7) relative to FITC-insulin (Figure 4.5) are probably due to the 
different conditions in the two sets of experiments, including temperature (37oC vs. room 
temperature), solution (culture medium vs. PBS), and structure of diffusing molecule 
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(secreted insulin vs. FITC-insulin). 
Overnight incubation of the apparatus in glucose-free PBS following the end of 
experiments with cells in the donor compartment indicated similar leakage of 
macromolecules as in the cell-free diffusion experiments (Figures 4.3 and 4.4). To further 
assess the toxicity of leaked con A, alginate-entrapped βTC3 cells were incubated in the 
donor compartment of the diffusion apparatus with con A-glycogen sandwiched between 
polycarbonate membranes under the following conditions:  DMEM with 20 mM glucose 
(material in gel state) for 6 hours; DMEM with 220 mM glucose (material in sol state) for 
6 hours; DMEM with 20 mM glucose for 3 hours followed by DMEM with 220 mM 
glucose for an additional 3 hours (material initially in gel state then converted to sol).  
Cell viability was measured by trypan blue at the end of each test.  Results are shown in 
Table 4.1.  No significant decrease in cell viability was observed at the end of each test. 
  
 
Table 4.1 Viabilities of alginate-entrapped βTC3 cells incubated in the donor 
compartment of the diffusion apparatus for 6 hours with material in sol or gel state, or 
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Figure 4.2 Macroscopic appearance of Concanavalin A-glycogen material exhibiting 
sol-gel transformations according to the glucose concentration in the surrounding 
















































Figure 4.3  Accumulation of FITC-insulin in the receiver compartments of two diffusion 
apparati containing FITC-insulin in the donor compartments.  Diamonds:  apparatus 1; 
squares:  apparatus 2.  Initially, both receiver compartments were insulin-free.  
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Figure 4.4  Accumulation of FITC-insulin in the receiver compartments of two diffusion 
apparati containing FITC-insulin in the donor compartments.  Squares:  apparatus 1; 
diamonds:  apparatus 2.  Initially, both receiver compartments were insulin-free.  
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Figure 4.5  Average effective diffusivities of FITC-insulin, calculated for the material in 
the gel and sol states, from a total of 8 experiments of the type shown in Figure 4.3 with 
apparatus 2 during the initial 360 min.  Glucose-free solutions were used in the diffusion 
apparatus for 180 min, after which glucose was added to both compartments to a 































































Figure 4.6  Accumulation of insulin in the receiver compartment of a diffusion 
apparatus containing alginate-encapsulated mouse βTC3 insulinomas in the donor 
compartment.  Initially, the material was in the gel state and the receiver compartment 
was insulin-free.  At 180 min, glucose was added to both compartments to a 
concentration of 220 mM causing the material to change to sol.  Straight lines are least 




























































Figure 4.7 Insulin effective diffusivities of the material from experiments with the 
diffusion apparatus containing βTC3 cells in the donor compartment.  Bar A 
corresponds to diffusivities calculated with the material always in the gel state during the 
experiment.  The data for bars B and C were calculated from experiments of the type 
shown in Fig. 6.  Bar B corresponds to diffusivities calculated with the material in gel 
state during the first 180 min of the experiment; after this, the material was converted to 


















               A                
gel (t=30-360 min)    
              B                  
gel (t=30-180 min)           
                 C                 














4.4.2 Mathematical modeling1 
To provide proof-of-concept that a hybrid construct based on constitutively 
secreting cells and on glucose-responsive material can release insulin with improved 
dynamics for physiologic glucose regulation, a mathematical model was developed to 
simulate the behavior of such a device.  The architecture considered is illustrated in 
Figure 4.8.  Cells dispersed in a gel are enclosed in a flat, cylindrical construct and are 
surrounded by a combination of the glucose-responsive material and a material 
permeable to oxygen and impermeable to insulin, such as silicone.  The 
glucose-responsive material, sandwiched between two membranes as before, occupies 
one of the flat surfaces of the apparatus.  The cylindrical and the second flat surfaces are 
occupied by the silicone-type material.  Thus, insulin diffusion occurs only through one 
of the flat surfaces, whereas oxygen diffusion can take place via both the flat and 
cylindrical surfaces of the device. 
The device is scaled for the diabetic mouse as a small animal model.  Previous 
work with βΤC3 cells has shown that 3x106 cells are needed to restore normoglycemia in 
NOD mice (C. Weber and S. Safley, personal communication).  It is assumed that the 
cells are dispersed in the gel at a density of 1.5x107 cells/mL, which has been shown to 
be appropriate for nourishment of all βΤC3 cells in hydrogel matrices of 1 mm thickness 
or less [138].  Thus, a volume of 0.2 mL accommodates the necessary number of cells; 
assuming the thickness of the gel to be 0.8 mm, the area of each flat surface is 2.5 cm2. 
 
_______________________________ 
1 Computational calculations of the mathematical modeling were performed by Jeff Gross 
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The equations describing the function of the device are as follows. 
 
( ) ( ) GinGoutGglueffinG nVqCCAkdt
VCd
−−= ,,
,    (1) 
( ) ( ) IoutIinIinseffinI nVqCCAkdt
VCd
+−−= ,,
,    (2) 
 
In the above equations, V is the volume inside the construct; CG,in (CG,out) and CI,in 
(CI,out) are the concentrations of glucose and insulin inside (outside) the construct, 
respectively; A is the surface area over which mass transport of glucose and insulin 
occurs; keffins (= Deffins/L) and keffglu (=Deffglu/L) are the effective permeabilities of insulin 
and glucose, respectively, via the glucose-responsive material; n is the cell density in the 
construct; and qG and qI are the specific rates of glucose consumption and insulin 
secretion, respectively. 










max,       (3) 
 
whereas qI is constant for constitutively secreting cells.  The values of all model 
parameters other than keff are given in Table 4.2. 
Two parameters of major significance in determining the behavior of the system 
are (i) the insulin permeability through the material in the sol and gel states, and (ii) the 
kinetics of material change from gel to sol and vice versa upon stepping up and down the 
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glucose concentration.  To generate the model simulations, an “idealized” material was 
considered, which differed from the current con A-glycogen material in the following two 
aspects: 
1. The material was assumed to exhibit gel-sol transformations within the 
physiologic range of glucose concentrations.  In contrast, the current con A-glycogen 
material needs to be exposed to higher than physiologic glucose concentrations to be 
converted from gel to sol.  In particular, the material was assumed to have effective 
permeabilities to insulin keffins of 2.1 x 10-6 cm/s and 7.4 x 10-5 cm/s at 4 mM and 15 mM 
glucose, respectively.  These are the values obtained with the existing con A-glycogen 
material sandwiched between the two polycarbonate membranes in experiments with 
cells (Fig. 7), except that the gel-sol changes occur at higher glucose concentrations.  
2. The material was assumed to exhibit the same kinetics of transformation from 
sol to gel as from gel to sol.  In contrast, the current con A-glycogen material is 
converted faster from gel to sol upon increasing the glucose concentration than it is from 
sol to gel upon decreasing the glucose concentration in the surrounding medium. The 













)()(      (4) 
 
where knew (t) is the dynamic response of the permeability in response to a glucose step 
change, equoldk  and 
equ
newk   are the permeabilities at equilibrium before and after the 
glucose concentration change, respectively, and t is time.  Assuming a value of 5 min for 
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parameter Km,t allows an approximate 90% phase change in 40 minutes, which has been 
observed experimentally for gel-to-sol tranformations.  The dynamic response of the 
material permeability to insulin in response to a step up and a step down in glucose is 
shown in Figure 4.9. It should be pointed out that a material with such improved 
characteristics, although currently unavailable, is realistic, as will be discussed later in 
this article. 
Model solutions were evaluated for a construct subjected to square waves of 
glucose concentration, from 4 mM for 4 hours to 15 mM for 2 hours back to 4 mM for 4 
hours, and so on.    Equations (1) and (2) were integrated from initial conditions 
CG,in (t=0) = 0  and 
CI,in (t=0) = 0   
and with CI,out constant and equal to 0.  Results for CI,in are shown in Figure 4.10A.  As 
expected, there is initially net accumulation of insulin in the construct, but after transients 





















Table 4.2 Values of model parameters used in simulating the function of the device in 
Figure 4.8. 
 
Parameter Symbol  Value 
Surface area of the membrane A  2.5 cm2 
Cell density in construct n  1.5x107 cells/ml 
Maximum specific rate of glucose consumption νmax,G  1.4µmol/(109cells·min) 
(from [138]) 
 
Saturation constant in Monod expression 
for glucose consumption rate Km,G  0.01 mM (from [138]) 
 
Specific rate of insulin secretion (constant) qI  4x10-5 µU/(105cells·min) 
(from [138])* 
 
Volume of construct V  0.2 mL 
 
* The constitutively secreting cells considered in the mathematical simulations were 
























































Figure 4.9  Kinetics of change of insulin permeability (keffins=Deffins/L) through the 
material considered in the mathematical simulations when the glucose concentration is 













































































































































Figure 4.10  Function of the construct shown in Figure 4.8 subjected to square waves of 
4 mM glucose for 4 hours and 15 mM glucose for 2 hours. 
A.  Accumulation of insulin in an initially insulin-free construct. 








4.5 Discussion  
A major challenge in developing a cell-based therapy for insulin-dependent 
diabetes consists of ensuring an appropriate cell source.  Recent clinical studies treating 
diabetes in humans by transplantation of allogeneic islets have received significant 
attention [3, 139, 140].  However, the problems of limited tissue availability and of side 
effects of long-term immunosuppression remain as substantial obstacles in such a 
therapeutic approach.  Autologous non-β cells, retrieved as a biopsy from the patient 
and genetically engineered for insulin secretion, constitute a promising alternative cell 
source.  Engineering cells for insulin secretion is straightforward and such cells relax the 
problems of tissue availability and immune acceptance. However, introducing 
physiologic glucose responsiveness is problematic.  Normal β cells exhibit a biphasic 
secretory response in response to a step up in glucose concentration.  The first phase of 
secretion corresponds to the fast insulin release from granules and lasts 10 to 15 minutes.  
The second phase occurs over a period of hours and is related to elevated proinsulin 
biosynthesis.  Insulin secretion stops quickly following a step-down in glucose level.  
Although it is unclear how closely a pancreatic substitute needs to mimic this type of 
secretion dynamics, genetically engineered non-β cells are generally far from this type of 
response, being either constitutive secretors of insulin or exhibiting glucose 
responsiveness but with sluggish dynamics [129-131, 133].  This paper presents a novel 
concept of a pancreatic substitute consisting of recombinant non-β cells and a material 
exhibiting glucose-responsive permeability to insulin which, as a whole, releases insulin 
with improved dynamics relative to the cells by themselves.  Although the construct 
does not mimic the insulin secretion dynamics of normal β cells, it does represent an 
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improvement relative to insulin injections.  
An ideal glucose-responsive material to be used in a hybrid device with cells 
should exhibit the following characteristics:  It should be specific to glucose and not 
react with other molecules in bodily fluids, exhibit rapid kinetics in its transformation 
from one state to the other, and function under the physiologic environment, such as 
neutral pH.  Additionally, it should be biocompatible or effectively enclosed in a 
semi-permeable barrier for biocompatibility, function with authentic insulin, i.e., it should 
not require insulin derivatization, and be stable in the long-term. 
There exist three types of glucose responsive-materials reported in the literature 
[20, 141-143]. The first type, based on glucose oxidase, has received significant attention 
in drug delivery and the development of glucose sensors [20, 21, 144-146].  Glucose 
oxidase catalyzes the conversion of glucose to gluconic acid and hydrogen peroxide, thus 
lowering the pH when this reaction occurs.  A hydrogel made from glucose oxidase and 
pH sensitive material may thus control the release of insulin by changing the structure of 
the pH-sensitive material when the reaction with glucose occurs. There exist, however, 
several drawbacks in using this type of material in a hybrid construct with cells.  First, 
the solubility of natural insulin decreases as the pH is lowered [15]; second, this type of 
material exhibits long time lags, of the order of hours, in its response [21]; and third, the 
reaction causes depletion of oxygen and production of gluconic acid and hydrogen 
peroxide, which are known to inhibit the activity of glucose oxidase [147] and are 
possibly harmful to the cells as well.   
A second type of material is based on phenylboronic acid, which can form a stable 
hydrogel with a polyol, such as poly(vinyl alcohol) [28, 29, 148, 149].  This hydrogel is 
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glucose-responsive, as it becomes dissociated in the presence of a competing polyol 
compound, such as glucose.  Using insulin modified so as to contain polyol residues, a 
material that releases modified insulin in response to glucose is created [150].  
Disadvantages of this approach include the need for derivatized insulin; and limited 
specificity towards glucose, as any polyol compound, such as plasma proteins and other 
saccharides, can react with phenylboronic acid. 
        The third type of glucose-responsive material is based on the glucose-binding 
protein con A, which is obtained from the jack bean plant.  Con A generally binds to 
saccharides containing α-D-mannose or α-D-glucose residues and appears to recognize 
terminal as well as internal saccharide residues. Con A exists as tetramers under neutral 
pH, with the tetrameric complex having four binding sites towards glucose.  When 
mixed with polysaccharides, such as glycogen and dextran, con A acts as a crosslinker 
forming a highly viscous gel.  Free glucose in the surrounding solution can 
competitively displace the polysaccharide and dissociate the gel into a sol [35, 36, 134, 
151].  In proof-of-concept studies on cell-material hybrid constructs, the con A-based 
material offers distinct advantages relative to the other glucose-responsive hydrogels for 
the following reasons: it is highly specific to glucose; it can function under physiologic 
environment; the kinetics of phase changes are relatively fast; the phase change is a 
reversible process; and it is not necessary to modify the insulin. Although con A is known 
to be immunogenic [32], the large molecular weight of the monomer (27,000) and 
especially of the tetramer that forms at neutral pH (108,000) enables the retention of the 
material in membranes, thus improving its biocompatibility.   
The experiments of this study show that glucose can induce the phase change of 
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the con A-based material, and that the diffusivity of secreted insulin under high glucose 
concentration (sol state) is approximately 3.5 times higher than the diffusivity under low 
glucose concentration (gel state, Figure 4.7).  The kinetics of gel to sol transformation 
are relatively fast, taking less less than 40 minutes in the apparatus of Fig. 1 to complete.  
On the other hand, the sol to gel phase change is slower.  Plausible reasons for this 
include: (i) the possible leakage of some material, which may explain the higher 
diffusivity through the 2nd sol state relative to the 1st in the sol to gel to sol experiments 
(Figure 4.4); (ii) the intrinsically slower kinetics of formation of the gel network, relative 
to its breakdown, as the former involves the diffusion of glucose out of the material and 
the re-association of con A with the polysaccharide chains.  Moreover, the possible 
entrapment of glucose in the material, following the change of the surrounding solutions, 
could delay the formation of the gel.  It has been suggested that reaction by-products 
formed during material preparation, e.g. B(OH)3, may become entrapped inside the 
hydrogel and affect the function of the material by slowing the kinetics of gel to sol 
transformation, however, such effects were not observed in this study.  
The glucose concentration of 220 mM used to accomplish the gel to sol 
transformation is much higher than the upper limit of the physiologic glucose 
concentration of approximately 15 mM.  The glucose concentration required for the 
phase change is expected to be different if con A is modified to alter its binding constant 
to glucose, or if another polysaccharide with different binding properties to con A is used 
[151, 152].  An example of the latter is offered by the work of Obaidat et al. [34], where 
with a synthetic polysaccharide the glucose concentration needed to achieve the phase 
change was 22 mM.  Reducing the thickness of the material may improve the kinetics of 
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gel/sol transformations.  Thus, by incorporating these modifications, a material could 
approximate the properties assumed in the modeling part of this work.  
The membranes used to sandwich the material constitute another important aspect 
of the device design.  The membranes should be biocompatible and have pores of a size 
that prevents leakage of glucose-responsive material components, while allowing 
transport of insulin without significant resistance.  Polycarbonate membranes have been 
used in hemodialysis applications, and although such membranes may not be suitable for 
long-term implantation, they are adequate for proof-of-concept experiments, in which 
high insulin permeability with low con A leakage are needed.  The 0.1 µm 
polycarbonate membranes did not completely prevent leakage of macromolecules, 
however, no toxic amounts of con A escaped over the course of experiments (Table 4.1).  
Such leakage may, however, result in significant immunogenicity in vivo.  Modifications 
of the con A-base material, such crosslinking con A with polysaccharide or increasing 
molecular weight by peglayting con A, should increase retention of the material and 
improve the flexibility in selecting the membranes  [38, 39]. 
 In mathematical modeling simulations aimed at demonstrating that sequestration of 
constitutively secreting cells by a glucose-responsive material produces a construct with 
improved secretion dynamics, an idealized material was assumed.  As previously 
discussed, it should be possible to improve both the glucose sensitivity and the 
transformation kinetics of the material by changing or derivatizing the macromolecules 
and by reducing the thickness of the sandwich configuration. According to the 
mathematical simulations, following the initial transients, the concentration of insulin 
inside the construct and the flux of insulin to the surroundings oscillated between 
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constant limits as the glucose concentration was cycled between 4 and 15 mM.  If the 
cells in the construct secrete at a constant rate, as assumed in this model, then the overall 
rate of insulin release from the construct is appropriate for restoring normoglycemia in 
the mice, the animal for which the device was scaled.  Incorporation of the material 
achieves a more physiologic regulation of insulin release, which occurs at a higher rate at 
high glucose than at low glucose concentration, as opposed to implanting the cells with 
an inert material, in which case insulin release would occur at a constant rate. 
It should be noted that the model predicts insulin accumulation inside the device 
to concentrations of the order of 3.5x106 µU/ml, much higher than those in the 
surrounding environment.  Experimentally, it has been found that insulin secretion from 
βTC3 cells is not feedback inhibited at insulin concentrations of 50,000 µU/mL 
(Tziampazis and Sambanis, unpublished results), and recombinant, constitutively 
secreting non-β cells are  expected not to be feedback inhibited, either, at such insulin 
concentrations.  However, it is unknown if the 70-fold higher insulin concentrations 
predicted to occur in the device have a negative effect on cells.  Increasing the 
diffusivity through the glucose-responsive material and/or of the area through which 
insulin transport occurs decreases proportionately the insulin concentration in the 
construct.  
Use of autologous cells offers significant flexibility in the type of material that 
can be used in an implantable device, as the cells do not need to be immunoprotected.  
The proof-of-concept studies presented in this paper indicate that it should indeed be 
feasible to associate constitutively secreting cells with a glucose-responsive material to 
generate a hybrid construct with insulin secretion dynamics closer to physiologic 
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compared to cells by themselves or encapsulated in an inert material, or compared to 
insulin injections.  Clearly, improvements are needed on several aspects of the material 
function prior to in vivo experiments, including:  (i) the material sensitivity should be 
improved towards the physiologic glucose range; (ii) the kinetics of gel-to-sol and, more 
so, of sol-to-gel transformations should be improved; and (iii) leakage of material 
components from the membrane sandwich should be minimized.  The latter is expected 




TISSUE ENGINEERING A PANCREATIC SUBSTITUTE BASED ON 




Genetically engineered cells offer a solution to the cell availability problem in tissue 
engineering a pancreatic substitute for the treatment of insulin-dependent diabetes.  
These cells can be non-beta cells, such as hepatocytes or myoblasts, retrieved as a biopsy 
from the same patient and genetically engineered to secrete recombinant insulin 
constitutively or under transcriptional regulation.  However, these cells exhibit 
sub-optimal insulin secretion dynamics and cannot, by themselves, restore 
normoglycemia in patients.  Our objective consists of associating genetically engineered 
cells with a glucose-responsive material, where the latter acts as a control barrier for 
insulin release, thus realizing a cell-material hybrid with improved secretion 
characteristics.  Proof-of-concept experiments were performed with insulinoma βTC3 
cells, HepG2 hepatomas, and C2C12 myoblasts, the latter two genetically modified to 
constitutively secrete insulin.  The control barrier consisted of concanavalin A (con 
A)-based glucose-responsive material.  Results demonstrated that the device released 
insulin at a higher rate in response to glucose challenges; in contrast, a device containing 
an inert hydrogel instead of glucose-responsive material released insulin at an essentially 
constant rate, irrespective of the surrounding glucose concentration.  The limitations of 




Insulin-dependent diabetes is a serious disease affecting more than 3 million people 
in the US.  The current treatment commonly consists of frequent blood glucose 
monitoring and multiple daily insulin injections.  However, this treatment does not 
provide the tight glycemic regulation afforded by a normally functioning pancreas, thus it 
cannot prevent long-term complications, which include cardiovascular disease, 
retinopathy and nephropathy [1, 9].  Closed-loop insulin delivery systems, consisting of 
a glucose sensor, a controlled pump, and an insulin reservoir, are promising at reducing 
the occurrences of hypo- and hyperglycemia.  However, the clinical application of such 
systems is still held back by technical difficulties, primarily the in vivo longevity and 
stability of glucose sensors [14]. 
Cell-based therapies have significant potential in correcting the drawbacks of the 
insulin delivery systems mentioned above.  Transplantation of human islets from 
cadaveric donors following the Edmonton protocol, which uses steroid-free 
immunosuppressive drugs, results in insulin independence for 80% of the treated patients 
over a period of 12 months [55].  However, as the number of available donors will never 
meet the large number of patients, and the risk of life-long immunosuppression is of 
concern [153], immunologically acceptable insulin-producing cells that exhibit proper 
secretion dynamics need to be sought.  Non-β cells, such as fibroblasts, myoblasts, and 
hepatocytes, can be retrieved as a biopsy from the same patient and engineered to express 
recombinant insulin [7, 83, 84, 154].  Due to their autologous nature, such cells relax the 
immune acceptance challenge, however, their insulin secretion is either constitutive or 
regulated at the transcriptional level, thus constant or sluggish in response to physiologic 
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stimuli and inadequate for glycemic regulation in higher animals and humans. 
Instead of relying on cellular and molecular tools, we earlier proposed the concept of 
improving the secretion profile of such β cell surrogates by sequestering them in a 
glucose-responsive material [155].  At low glucose concentrations, the material is in a 
gel state that exhibits low insulin permeability, whereas at high glucose levels the 
material becomes a sol that exhibits a higher permeability to insulin [134, 155].  Thus, at 
low glucose concentrations, a higher fraction of the insulin secreted by cells accumulates 
within the construct, and the insulin release rate is relatively low.  When the construct is 
exposed to high glucose, the material becomes a more permeable sol, and the insulin 
release rate from the construct is higher.  As the time constant of the gel to sol and of sol 
to gel transformations is shorter than the (infinite) time constant of constitutively 
secreting cells or the (long) time constant of transcriptionally regulated cells, the kinetics 
of material transformation determine the kinetics of insulin release from the entire device.  
In this article, we report the development of a disk-shaped prototype incorporating 
as part of its boundary a concanavalin A (con A)-based glucose-responsive material and 
containing one of three different cell types:  mouse insulinoma βTC3 cells, human 
HepG2 hepatomas, and murine C2C12 myoblasts, the latter two genetically engineered 
for constitutive insulin secretion.  Control constructs were fabricated in the same fashion, 
except that an inert material was used instead of the conA-based barrier.  Insulin release 
from the devices was characterized by subjecting them to two square waves of glucose, 
each lasting two hours.  The potential of such cell-material hybrid constructs in treating 
diabetes and the limitations that need to be overcome prior to in vivo applications are 
discussed.     
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5.3 Materials and Methods 
5.3.1 Glucose-Responsive Material  
The preparation of con A-glycogen material was based on the published protocol 
by Taylor et al [134]. Briefly, glycogen (Sigma Chemical Co., St. Louis, MO) was 
dissolved in PBS at 60% (w/v) and mixed with a 0.2M NaIO4 solution at 1:1 volume ratio 
for 24 hours in the dark.  The hydrogel was formed by mixing the resultant glycogen 
solution with a 15% w/v con A (Amersham Biosciences, Piscataway, NJ) solution in PBS 
at a 1:1 volume ratio.  The gel was left at room temperature 24 hours followed by 1 hour 
immersion in 1 mg/ml NaBH4 at 4°C.  Finally, the gel was washed at least three times 
with PBS buffer and stored in PBS at 4oC for later use.          
 
5.3.2 Cell Culture and Transfection  
βTC3 cells were obtained from the laboratory of Shimon Efrat, Albert Einstein 
College of Medicine, Bronx, NY.  Cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, Sigma) supplemented with 15% horse serum (Sigma), 2.5% fetal 
bovine serum (Hyclone, Logan, UT), 1% penicillin/streptomycin (Mediatech, Herndon, 
VA), and L-glutamine (Gibco, Grand Island, NY) to a final concentration of 6 mM.  
HepG2 human hepatoma cells (ATCC, Manassas, VA, USA) and C2C12 mouse skeletal 
myoblasts (ATCC) were cultured in DMEM (Mediatech) supplemented with 10% fetal 
bovine serum (Hyclone) and 1% penicillin/streptomycin (Mediatech).  C2C12 
myoblasts were induced to differentiate into myotubes by culturing in low serum medium 
consisting of DMEM (Mediatech) supplemented with 2.5% hourse serum (Hyclone) and 
1% penicillin/streptomycin (Mediatech) [7]. Myotube formation was observed under the 
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microscope 3 days after the cells were switched to the low serum medium.  In this study, 
C2C12 cells were transfected as myoblasts. 
The plasmid, CMV/ Furin-B10 PPI cDNA/ PuroR, used to engineer HepG2 and 
C2C12 cells into stable insulin-secreting cells, was constructed as previously described 
by Tang and Sambanis [86] and is shown in Figure 5.1A.  Briefly, a DNA fragment 
containing IRES and puromycin resistance genes from plasmid pIRESpuro (Clontech, 
Palo Alto, CA) was connected to the 3’-end of the Human preproinsulin (PPI) cDNA in 
the vector, CMV/ Furin-B10 PPI cDNA (Figure 5.1B).  The PPI cDNA was 
furin-compatible with a His B10-to Asp mutation (B10 mutation), and was a kind gift of 
Genetech, San Francisco, CA [72].  The expression cassette of plasmid CMV/ 
Furin-B10 PPI cDNA/ PuroR generated a bicistronic mRNA and directed the synthesis of 
both the insulin and puromycin resistance protein, thus facilitating the selection process 





Figure 5.1 Plasmid structures 
A: CMV/ Furin-B10 PPI cDNA/ PuroR. 
B: CMV/Furin-B10 PPI cDNA from [86]. 
 
PCMV  Intron IRES Poly(A) Enhancer PPI cDNA 




When HepG2 and C2C12 cells reached about 60% confluency, they were 
treansfected using the FUGENE 6 reagent (Roche, Indianapolis, IN) according to the 
manufacturer’s protocol.  In a T-75 flask, cells were incubated 24 hours with the culture 
medium (without antibiotics) containing the plasmid (15 µg) and the FUGENE 6 reagent 
(45 µl).  After transfection, cells continued to be cultured for recovery until they were 
ready to be split.  When the transfected cells reached about 90% confluency, cells were 
trypsinized and split in 1:100 ratios into 100 mm culture dishes.  During the selection 
process, which lasted over one month, cells were cultured in the presence of 2 µg/ml 
puromycin.  Only cells that expressed the puromycin resistance gene survived under the 
selection pressure.  Surviving cells formed colonies, which could be clearly seen under a 
microscope, then cells were retrieved by cloning disks and plated into the wells of a 
24-well plate.  In all subsequent experiments, engineered cell lines were cultured in 
media supplemented with 1 µg/ml puromycin.  
 
5.3.3 Cell Encapsulation 
 To facilitate cell loading into hybrid constructs, βTC3 cells and recombinant 
HepG2 and C2C12 cells were encapsulated in 2% alginate (ISP Inc., San Diego, CA) at a 
density of 7x107 cells/ml of alginate following the general protocol published by Stabler 
et al [71], except that a poly-L-lysine membrane and a final alginate coating were not 
applied.  Briefly, cells from confluent monolayer cultures were detached by 
EDTA-trypsin (Sigma).  A sample of the cell suspension was used for cell counting with 
trypan blue (Sigma); the rest of the suspension was centrifuged for 4 minutes at 110 g, 
and pellets were mixed with sodium alginate sterilized by filtration through a 0.2-µm 
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syringe filter (Pall Life Sciences, Ann Arbor, MI).  Alginate beads of approximately 700 
µm diameter were formed by passing the cell-alginate suspension through an electrostatic 
bead generator (Nisco Engineering Inc., Zurich, Switzerland) into a 1.1% CaCl2 solution.  
Beads were washed twice with culture medium, incubated overnight on an orbital shaker, 
and loaded in constructs for secretion experiments the following day.  To ensure that 
recombinant HepG2 and C2C12 cells were functional once encapsulated, beads were also 
cultured in T-flasks on a rocking platform for up to 10 days with medium changes every 
one to three days, depending on the cell growth rate.  At different times, bead samples 
were withdrawn for histology and viability assessment by trypan blue staining as 
described in the analytical techniques.  As βTC3 cells have been shown to retain their 
function after alginate encapsulation [71], T-flask cultures of alginate beads with these 
cells were not performed. 
 
5.3.4 Construct Design and Fabrication 
The geometry of the cell-material hybrid construct is shown in Figure 5.2.  Two 
polycarbonate plates (3 mm in thickness, 6 cm in diameter), each with a 3.7 cm diameter 
hole in the center (see the top view of the construct in Figure 5.2), constituted the main 
structural components of the construct.  Two silicon sheets (2 mm in thickness, 4.7 cm 
in diameter), also each with a 3.7 cm diameter hole in the center, were used to separate 
the membranes that enclosed the glucose-responsive material and the cells.  The 
material was sandwiched between one 0.02 µm pore size Anodisc membrane (Whatman 
Inc., Clifton, NJ), positioned between the material and the cells, and one 0.1 µm pore size 
polycarbonate membrane (Whatman Inc.), positioned between the material and the 
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surrounding medium.  Both of these membranes are permeable to insulin.  To 
minimize leakage of con A towards the cell compartment, while not excessively 
restricting diffusion of insulin through the membranes themselves, the smaller pore size 
membrane was used to separate the cells and the material and the larger pore size 
membrane was placed between the material and the surrounding medium.  The cell 
compartment was sequestered on the other side by a polyethersulfone membrane of 3kDa 
molecular weight cutoff (Pall Life Sciences), which allowed passage of small molecules, 
such as glucose and oxygen, for cellular nourishment, but effectively excluded insulin.   
In experimental constructs with glucose-responsive material, pieces of con 
A-glycogen gel of approximately 2 ml total volume were transferred by a spatula and 
used to fill the hole of the silicon sheet on top of the Anodisc membrane.  Then, the 
polycarbonate membrane was positioned on top of the material to complete the material 
barrier.  Two types of control constructs were fabricated, one with calcium alginate and 
the other with culture medium in place of con A-glycogen.  In the alginate control, the 
material compartment was first assembled with the Anodisc and polycarbonate 
membranes and the polycarbonate plates sandwiching the silicon sheet tightly.  Sodium 
alginate (ISP Inc.), filter-sterilized through 0.2 µm syringe filter (Pall Life Sciences), was 
then injected, filling the space in between the membranes.  The whole construct was 
immersed in a 1.1% CaCl2 solution for 30 minutes to ensure gelation of the alginate 
inside the barrier.  For the control construct with culture medium, the medium was 











Figure 5.2 Cell-material hybrid construct configuration.  The con A-glycogen material 
was placed in the 3.7 cm diameter hole of a 2 mm-thick silicon sheet and was sandwiched 
between a 0.1 µm pore-size polycarbonate and a 0.02 µm pore-size Anodisc membrane.  
The cell compartment consisted of alginate-encapsulated insulin-secreting cells 
positioned in the 3.7 cm diameter hole of a 2 mm-thick silicon sheet and bounded on one 
side by the material compartment and on the other side by a 3k Dalton MWCO 
polyethersulfone membrane.  Polycarbonate plates with 6 screws were used to fix 
everything in place.  Control constructs were fabricated in the same way, except that 
calcium alginate or plain culture medium was used instead of con A-glycogen.  The 
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To assemble the cell compartment, 1 ml of alginate-encapsulated insulin-secreting 
cells were first placed on the top of the 3 kDa MWCO cellulose ester membrane on the 
lower polycarbonate plate.  The material sandwich assembled as described previously 
was then laid on top of the cell compartment, followed by the material-side polycarbonate 
plate, and the whole construct was tightly assembled by screws.  Approximately 1 ml of 
the culture medium was then injected into the cell compartment.  The assembled 
construct was immediately immersed in a beaker containing 50 ml of culture medium 
with 25 mM glucose and supplemented with serum, as described in the cell culture 
section for the different cell lines.  The beaker and the construct were then placed inside 
a tissue culture incubator on top of an orbital shaker that provided adequate mixing. 
 
5.3.5 Characterization of Insulin Release from Constructs 
  Each construct was cultured for 20 hours prior to glucose concentration 
changes to allow insulin to accumulate inside the cell compartment.  Two square-waves 
of glucose were implemented to test the glucose responsiveness of the hybrid construct.  
Immediately prior to the glucose changes, the culture medium was replaced with fresh, so 
when an experiment started at t=0, the surrounding medium was insulin-free and 
contained 25 mM of glucose.  Following incubation for 2 hours in this medium, 2.0 g of 
glucose was directly added to the beaker to increase the glucose concentration to 220 mM.  
For the glucose step down 2 hours later, the medium was completely replaced with fresh 
culture medium containing 25 mM glucose, and the cycle was repeated once more.  
Samples were collected every 30 minutes during experiments, and the same amount of 
culture medium was added back to maintain constant volume inside the beaker.  All 
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samples were stored at -20oC for later insulin assay.  At the end of the experiment, the 
constructs were disassembled, and the alginate-encapsulated cells were collected to 
assess cell viability.  
 
5.3.6 Analytical Techniques 
5.3.6.1 Cell Viability 
To measure the viability of alginate-encapsulated cells, beads were dissolved in a 
2.2% sodium citrate solution, and the resulting cell suspension was centrifuged for 3 
minutes at 110 g.  Pelleted cells were re-suspended in culture medium and mixed with 
trypan blue (Sigma) at 1:1 volume ratio.  Cell viability in the final suspension was 
determined on a hemocytometer under a microscope by trypan blue exclusion.  
 
5.3.6.2 Insulin Assay 
Insulin secreted by βTC3 and HepG2 cells was assayed by rat insulin 
radioimmunoassay (Linco Research, St. Charles, MI, USA). The antibody used in the 
assay had a 100% reactivity against mouse and human insulin and a 69% 
cross-reactivity against human proinsulin.  Insulin secreted by C2C12 cells was 
assayed by a human-specific insulin radioimmunoassay, which had 0.02% 
cross-reactivity to human proinsulin.   This ensured that the immunoreactive insulin 
secreted by C2C12 cells was mature insulin. 
 
5.3.6.3 Histology 
For histology, alginate beads were fixed with a 3% glutaraldehyde solution, then 
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embedded in paraffin blocks. Blocks were later sectioned by a microtome, and the 
obtained slides were stained with hematoxylin/eosin (H/E). 
 
5.4 Results 
5.4.1 Construct with βTC3 cells 
Results with constructs consisting of βTC3 cells and glucose-responsive material 
(experiment) or culture medium (control) are shown in Figure 5.3.  βTC3 cells are 
glucose-responsive but hypersensitive, as they express the GLUT-1 instead of the 
GLUT-2 glucose transporter and hexokinase instead of glucokinase [5, 68].  Thus, the 
cells secreted insulin constitutively under the 25-220 mM glucose used in this experiment.   
The average insulin release rate over each indicated time period was calculated from the 
slope of the least squares fit of the released insulin concentration vs. time data; each rate 
was normalized to the corresponding low glucose release rate during the 0-2 hour period, 
which was set equal to 1.  For the experimental construct, the insulin release rates 
changed with the step changes of glucose:  the rates during high glucose were, on 
average, 2- to 3- fold higher than those during the low glucose periods.  On the other 
hand, insulin release rates from the control construct did not respond to changes in the 




































































Figure 5.3 Insulin release profiles from hybrid construct of alginate-encapsulated 
insulin-secreting βTC3 cells with con A-based material (experiment, ■) and with culture 
medium (control, □).  In each independent experiment, insulin release rates were 
normalized to the rate during 0-2 hour, which was set equal to 1.  ♦, *, #, and ▲ 
indicate pair-wise statistical comparisons using a one-tailed t-test, p<0.05.  Error bars 











5.4.2 Construct with genetically engineered non-β cells 
An autologous cell therapy approach for insulin-dependent diabetes should be 
based on non-β cells that can be retrieved as a biopsy and genetically engineered to 
secrete insulin.  Such cells include hepatocytes, retrieved as a biopsy from the liver, and 
myoblasts, retrieved as a biopsy from muscle tissue.  In proof-of-concept experiments, 
human HepG2 hepatomas and mouse C2C12 myoblasts were genetically engineered for 
constitutive expression of insulin, encapsulated in calcium alginate beads and associated 
with glucose-responsive material (experiment) or with calcium alginate (control) in the 
disk-shaped device shown in Figure 5.2.  The construct responses to step changes in 
glucose concentration were then evaluated. 
 
5.4.2.1 Construct with HepG2 cells 
HepG2 cells were genetically engineered by chemical transfection with the CMV/ 
Furin-B10 PPI cDNA/ PuroR plasmid shown in Figure 5.1A.  Clones that survived under 
the selection pressure secreted insulin constitutively at a rate of 9.5±2.3 µU/(hour•105 
cells).  Cells were encapsulated at a density of 7x107 cells/ml of alginate prior to 
incorporation in the hybrid construct.  Histology sections of alginate encapsulated cells 
propagated in T-flasks on an orbital shaker are shown for different time points in Figure 
5.4.  Cells proliferated in the alginate beads, and since no poly-L-lysine coating was 
applied, beads became unstable and cells started protruding out of them by day 9.  This 
phenomenon was not observed with beads incorporated in constructs, as all construct 
experiments were terminated by day 3 after bead preparation.  Additionally, 
trypsinization and encapsulation had no short-term effect on insulin secretion from 
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HepG2 cells, as the per-cell secretion rate from calcium alginate-entrapped cells two days 
post-encapsulation was the same as the secretion rate from monolayer cultures.   
Results from experimental and control constructs with HepG2 cells are shown in 
Figure 5.5.  In the control construct, insulin-release rates stayed at the same level 
through the two glucose square-waves in the surrounding environment (P>0.1 between 
high and low glucose periods).  On the other hand, in the experimental construct, 
insulin-release rates responded to changes in the surrounding glucose concentration.  In 
fact, the average rates showed an 8-fold difference between high and low glucose.  
Contrary to the experiment with βTC3 cells, in the experiment with recombinant HepG2 
cells and the glucose-responsive material the insulin-release rate during a 25 mM glucose 
period was higher than the rate during the prior 25 mM glucose period.  For example, 
the rate during the 4-7 hour period was higher than that during the 0-2 hour period 
(p<0.001).  This appeared to be due to degradation and loss of con A-glycogen material 
exaggerated by the presence of the high FBS concentration in the HepG2 culture medium.  
This possibility was further investigated in experiments with C2C12 cells (see below).  
Even though the material was not able to completely revert to the original gel state after 
lowering the glucose level, the insulin release rate during a 25 mM glucose period was 
always statistically lower than that during the previous 220 mM glucose period (e.g. 

















Figure 5.4 Representative histology cross-sections of alginate-encapsulated ΗepG2 cells 
on days 3 and 6 post-encapsulation.  Cells were encapsulated at an initial density of 









































































Figure 5.5 Insulin release profiles from hybrid construct of alginate-encapsulated 
insulin-secreting HepG2 cells with con A-based material (experiment, ■) and with 
alginate (control, □).  In each independent experiment, insulin release rates were 
normalized to the rate during 0-2 hour, which was set equal to 1.  ♦, *, #, and ▲ 
indicate pair-wise statistical comparisons using a one-tailed t-test, p<0.05.  Error bars 










5.4.2.2 Construct with C2C12 cells 
Stable C2C12 clones isolated under antibiotic selection secreted recombinant 
insulin constitutively when cultured as undifferentiated myoblasts or as differentiated 
myotubes in monolayer cultures.  The insulin-secretion rate from undifferentiated 
C2C12 myoblasts was 17.5±3.4 µU/hr-105 cells, whereas C2C12 myotubes secreted 
insulin at a rate of 43.4±9.5 µU/hr-105 cells.  The higher insulin-secretion rate from 
myotubes relative to undifferentiated C2C12 cells is consistent with literature reports [96].  
C2C12 were encapsulated in alginate at a density of 7x107 cells/ml of alginate and were 
propagated in either FBS or HS-supplemented culture media for 10 days.  Histology 
sections of beads at different time points are shown in Figure 5.6.  Unlike HepG2 cells, 
C2C12 cells proliferated slowly after encapsulation.  C2C12 cells are reportedly unable 
to differentiate when plated on alginate sheets [72] and remained undifferentiated in 
alginate beads in this study, too.  Consequently, their growth patterns were similar in the 
FBS and HS-supplemented media, as indicated by histology.  Alginate entrapped C2C12 
cells secreted insulin post-encapsulation in both types of culture medium used, and the 
per-cell secretion rate was 9.1±1.7 µU/hr-105 cells, lower than rates measured in 
monolayer cultures.  
Although C2C12 cells were not able to differentiate in alginate via exposure to 
low-serum medium, construct experiments were still performed with both 10% FBS and 
2.5% HS-supplemented media to further investigate whether a high FBS concentration 
caused the con A-glycogen degradation observed with HepG2-containing constructs.  
Insulin-release profiles from the C2C12-based constructs are shown in Figures 5.7 and 
5.8.  Insulin release rates from control constructs were at the same level in high and low 
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glucose with both types of serum.  On the other hand, the insulin release rates from 
experimental constructs responded to changes in glucose concentration, but the degree of 
induction differed with type of culture medium.  With 2.5% HS-supplemented medium, 
the insulin release rates under low glucose remained constant (P>0.3 between values at 
4-7 hours and 9-12 hours), and the insulin release rate under high glucose was, on 
average, 5-fold higher than the corresponding low glucose rate (Figure 5.7).  This result 
correlated well with the experiments with βTC 3 cells (Figure 5.3), in which the culture 
medium contained 2.5% FBS and 15% HS.  With the 10% FBS-supplemented medium, 
results (Figure 5.8) were similar to those obtained with the HepG2-containing constructs, 
in which the same type of medium was used (Figure 5.5).  Insulin release rates during 
the high glucose periods were all higher than that the rates during the low glucose periods, 
which demonstrated that the release of insulin from the experimental construct was 
glucose-dependent.  However, the insulin release rates during the 25 mM glucose 
periods increased with time in the experiment:  the rate during the 4-7 hour period was 
3.3-fold higher than the rate during the 0-2 hour period; and the rate during the 9-12 hour 
period was 5.5-fold higher than that during the first low glucose period.   Furthermore, 
insoluble particulate matter was observed in the containers at the end of the 20 hour 
incubation period prior to the glucose concentration step changes only when the high 
FBS medium was used with both the HepG2 and C2C12 cells as insulin source.  Thus, it 
appears that the high concentration of FBS exaggerated the degradation and loss of con 













                            
Day 2 in 10%FBS        Day 7 in 10% FBS      Day 7 in 2.5% HS 
 
Figure 5.6 Representative histology cross-sections of alginate encapsulated 
insulin-secreting C2C12 cells on days 2 and 7 for cultures in medium with 10% FBS and 
on day 7 for cultures in medium with 2.5% HS.  Cells were encapsulated at an initial 

















































   
   
























Figure 5.7 Insulin release profiles from hybrid construct of alginate-encapsulated 
insulin-secreting C2C12 cells with con A-based material (experiment, ■) and with 
alginate (control, □).  Media used were supplemented with 2.5% HS.  In each 
independent experiment, insulin release rates were normalized to the rate during 0-2 hour, 
which was set equal to 1.  ♦, *, #, and ▲ indicate pair-wise statistical comparisons 































































Figure 5.8 Insulin release profiles from hybrid construct of alginate-encapsulated 
insulin-secreting βTC 3 cells with con A-based material (experiment, ■) and with 
alginate (control, □).  Media used were supplemented with 10% FBS.  In each 
independent experiment, insulin release rates were normalized to the rate during 0-2 hour, 
which was set equal to 1.  ♦, *, #, and ▲ indicate pair-wise statistical comparisons 










5.4.3 Cell Viability 
The viabilities of different cell lines in experimental and control constructs are 
shown in Figure 5.9.  In control constructs, βTC3 and C2C12 cells maintained 
viabilities above 60% at the end of 32 hour-long tests.  However, the viability of HepG2 
cells in control constructs dropped to below 50% by the end of tests, which suggested that 
HepG2 cells were more sensitive to the sub-optimal environment inside constructs.  Cell 
viabilities in experimental constructs were statistically lower than those in the 







































Figure 5.9 Viabilities of alginate-encapsulated cells at the end of construct experiments with con A-based 
material (experiment, ■) and with culture medium (βTC 3 cells (n=3)) or alginate (HepG2 (n=4) and 
C2C12 (n=3) cells) (control, □).  * indicate pair-wise statistical comparisons using a one-tailed t-test, 
p<0.03.  Error bars indicate standard deviation. 
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5.5 Discussion 
Glycemic regulation in higher animals and, eventually, humans requires delivery of 
insulin in close response to physiologic needs.  Normal islets accomplish this regulation 
through control of both insulin biosynthesis and secretion by glucose and other metabolic 
signals.  In response to a step up in glucose concentration, islets exhibit a biphasic 
secretory response.  The rapid first phase of insulin secretion results from the release of 
pre-synthesized insulin already stored in secretory granules; the second, more prolonged 
phase of secretion is due to elevated insulin biosynthesis and/or the preparation of 
another group of granules for release [52, 53]. 
Non-β cells that can be retrieved as a biopsy from a patient can be engineered to 
express recombinant insulin but generally lack a system of secretory granules that is 
responsive to glucose.  Introducing regulation at the transcriptional level via the use of 
glucose-responsive promoters is helpful, but the resulting cells still cannot release insulin 
acutely in response to a glucose challenge [83, 84, 132, 156].  In this work, we 
developed and characterized a prototype consisting of a constitutively secreting β cell 
line or recombinant non-β cells sequestered in a glucose-responsive material.  We 
demonstrated that the insulin released from the prototype was responsive to glucose 
challenges, whereas if an inert material was used, the insulin release rate did not respond 
to the same glucose concentration changes. 
Among non-β cells, hepatocytes and myoblasts are particularly promising for the 
development of β-cell surrogates.  Hepatocytes can be obtained as a biopsy, they express 
GLUT2 and glucokinase, two major glucose-sensing components in β cells that are 
involved in regulating insulin secretion, and hepatic expression of insulin under 
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transcriptional regulation has been repeatedly shown to provide some glycemic control in 
diabetic rodents [83, 132].  However, due to the absence of an acute secretory response, 
it is doubtful that engineered hepatocytes will provide appropriate glycemic regulation in 
higher animals, without the risk of hypoglycemic episodes.  Myoblasts also lack a 
regulated secretion pathway, but relative to hepatocytes they offer the advantage of easier 
retrievability as a biopsy, capability in amplifying into large cell number, and the ability 
for differentiation into stable myotubes.  Moreover, myoblasts have been engineered to 
constitutively secrete a number of therapeutic proteins, such as ciliary neurotrophic factor 
[88], erythropoietin [89], human factor IX [90, 91], and human growth hormone [93].  
Prior to implantation, myoblasts can be differentiated into myotubes after encapsulation 
inside polyethersulfone hollow fibers [88, 89], or they can be tissue-engineered in vitro 
into a bioartificial muscle [93].  Both approaches have yielded promising in vivo results 
demonstrating the efficacy of recombinant myoblasts as a living protein delivery device.   
In this work, human HepG2 hepatomas and murine C2C12 myoblasts were stably 
transfected with a human preproinsulin cDNA mutated at the B/C and C/A junctions, so 
that the ubiquitous endoprotease furin could process proinsulin into an insulin-like 
molecule.  Additionally, the preproinsulin cDNA contained a mutation at the B10 site to 
enhance insulin stability [72].  For ease of handling, cells were encapsulated in alginate 
matrix.  Histology sections of beads at different time points and insulin-secretion tests 
showed that encapsulation did not compromise the function of HepG2 and C2C12 cells to 
an extent that would be incompatible with the objectives of this study.   
Besides cells, a second important component of the hybrid construct is the 
glucose-responsive material.  Such types of material have been used in developing 
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glucose sensors and in controlling the release rate of insulin from a drug delivery device.  
However, in the latter type of device, loss of insulin activity with time and the need to 
periodically refill the reservoir are problematic.  Insulin-secreting cells result in a 
continuously refilled reservoir, thus alleviating the problems mentioned above.  Various 
types of glucose-responsive material have been proposed [28, 134, 144].  For use in a 
hybrid device with cells, an ideal glucose-responsive material should exhibit the 
following characteristics:  it should function under physiologic conditions, including pH, 
temperature, and physiologically relevant glucose concentrations; release no toxic 
compounds harming the cells; function with the form of insulin released by the cells, i.e., 
does not require modified insulin; exhibit high glucose specificity, rapid kinetics, and 
long-term stability.  Although far from ideal, the con A-based glucose-responsive 
material meets some of the above requirements, including the ability to function with the 
insulin secreted by cells at physiologic pH and temperature. 
Con A is a lectin, which forms a tetramer under physiologic conditions and has four 
binding sites toward free glucose or glucose residues in a polysaccharide chain. When 
con A is mixed with polysaccharides, it acts as a crosslinker forming a highly viscous gel.  
When exposed to a high glucose solution, the gel dissociates into a sol due to the 
competitive binding reaction between free glucose and the glucose monomers in a 
polysaccharide chain toward con A.  Based on previously reported diffusion chamber 
experiments [155], the time required for a 2 mm thick material to complete the phase 
changes is of the order of 30 minutes.  It is possible to shorten this response time by 
reducing the thickness of the material.  The glucose concentration of 220 mM used to 
induce material transformation is well beyond physiologic conditions.  The 
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responsiveness of the material can be brought towards the physiologic domain by using 
modified con A or other types of polysaccharides [157].  Additionally, factors in fetal 
bovine serum apparently caused degradation of the con A-based material.  All these 
constitute areas in which material improvements are needed prior to in vivo experiments. 
Among the insulin-secreting cells used in these experiments, HepG2 cells appeared 
to be less tolerant to the unfavorable conditions inside the construct that might include 
hypoxia, and possibly high insulin concentrations in the cell compartment.  It is unclear 
whether the recombinant cells in this study were subject to insulin feedback inhibition.  
Nonetheless, such inhibition might offer the advantage of preventing excessive insulin 
accumulation inside the construct.  The lower cell viability in experimental vs. control 
constructs is not surprising, as leaked con A could have a toxic effect towards cells.  
Tethering con A to the polysaccharide to prevent leakage is thus another modification that 
may improve the functionality of the construct, especially in the long-term.  
     Insulin secretion needs to be tightly regulated by glucose to achieve 
normoglycemia in higher animals and, eventually, humans.   In cell-based therapies, 
potentially autologous non-β cells engineered for insulin secretion are promising, as they 
are easily available by biopsy and do not entail immune acceptance problems.  Although 
such cells are easily engineered for insulin secretion, introducing appropriate glucose 
responsiveness is a daunting task.  Results presented in this paper indicate that it is 
indeed feasible to associate constitutively secreting cells with a con A-glycogen 
glucose-responsive material to generate a hybrid construct with closer to physiologic 
insulin secretion dynamics compared to cells by themselves or encapsulated in an inert 
material.  Although the con A-glycogen material is adequate for proof-of-concept 
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studies, modifications are needed to improve the kinetics of sol-gel transformation, the 








































TISSUE ENGINEERED PANCREATIC CONSTRUCT BASED ON PEG-CON A 
GLUCOSE-RESPONSIVE MATERIAL AND INSULIN-SECRETING CELLS 
 
6.1 Abstract 
The proposed cell-material hybrid construct consisted of glucose-responsive 
material and insulin-secreting cells exhibited insulin-release in response to glucose step 
changes in the surrounding environment.  However, the glucose sensitivity of the con 
A-glycogen material we previously used was far beyond physiologic conditions.    In 
this study, we explored the potential of improving the glucose-sensitivity of con A-based 
material through the use of PEGylated con A molecules.  Studies showed that 
PEGylated con A molecules retained the ability in forming glucose-responsive material 
with glycogen, moreover, the resulting material has improved glucose sensitivity relative 
to the material formed by unmodified con A molecules.  Incorporation of the improved 
con A-based material into our cell-material hybrid construct, which contained 
constitutively insulin-secreting myoblasts as the insulin source, the construct released 
insulin in response to glucose step changes closer to physiologic range.    
 
6.2 Introduction 
A major concern in developing a cell-based therapy for treating insulin-dependent 
diabetes (IDD) is the cells being used, which have to be immune acceptable at clinically 
relevant amounts, and have to secrete insulin in response to glucose step-changes with 
kinetics similar to those of β cells.   Cells of non-β origin, such as liver [84, 85] and 
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muscle cells [7], can be retrieved from a patient and genetically engineered ex vivo to 
become insulin-secreting cells.  These autologous cells are accepted immunologically 
and relax the cell availability concerns.  However, as β cells regulate insulin secretion in 
a sophisticated mechanism from gene transcription, translation, to the secretory pathway, 
the task of engineering non-β cells merely at the gene level becomes very challenging in 
having cells exhibiting proper secretion kinetics [86].   
 Instead of relying on cellular and molecular tools, we earlier proposed the first 
prototype of a cell-material hybrid construct, in which the release of insulin secreted by 
the cells was controlled by the phase changes of a material barrier composed of 
glucose-responsive material [155].  Among different types of glucose-responsive 
material developed for the glucose sensor and insulin delivery [21, 26, 36], we have 
chosen a concanavalin A (con A)-based material in our proof-of-concept studies.  In that 
study, we were able to change the continuous insulin-secreting characteristic of the cells 
to glucose-responsive insulin release from the device (Chapter 5).  However, there exist 
problems with the con A-based material that need to be addressed prior to any in vivo 
tests, in particular, the glucose sensitivity of the con A-glycogen material used, which 
was far from the physiologic range.    
Con A is a lectin, which exists as tetramer with four glucose-binding sites under 
physiological conditions [32].  When mixed with polysaccharides containing pendent 
glucose molecules, con A acts as a crosslinker to the polysaccharides resulting in the 
formation of a viscous gel.  Exposing the gel to a glucose solution, a 
competitive-binding reaction between free glucose and glucose on polysaccharides chains 
toward con A binding sites occurrs.  If most of the con A binding sites are occupied by 
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free glucose, the gel dissociates into a sol [36, 134, 157].  Due to the multivalence 
effects [158], con A molecules tend to have higher binding affinity towards 
polysaccharides than free glucose, hence, the glucose concentration required to break 
down the gel structure is usually very high.  Potential solutions in improving the glucose 
sensitivity of con A-based material includes using a synthetic polysaccharide that has 
lower con A binding affinity, or modifying the con A molecules so as to have a higher 
binding affinity toward free glucose and a lower binding affinity toward polysaccharides.  
Park et al [8] have shown that by PEGylating the con A molecule, one can increase 
its binding affinity towards free glucose up to 4-fold.  Moreover, due to steric hindrance, 
it is also expected that PEGylated con A would have lower binding affinity towards 
polysaccharides.  In addition, PEGylation is a tool widely used in improving the 
biocompatibility and stability of proteins [159, 160], so using PEGylated con A could be 
advantageous in reducing the immunogenicity of the resulting gel.  In this study, we 
demonstrated that the glucose sensitivity of con A-based material can be improved by 
using PEGylated con A molecules.  Experiments with the cell-material hybrid construct 
containing the improved material and continuous insulin-secreting myoblasts were also 
performed, which provided further proof that it is indeed feasible to develop a 
tissue-engineered pancreatic substitute combining the genetically engineered cells and the 




6.3 Materials and Methods 
6.3.1 Con A PEGylation and preparation of glucose-responsive material 
Con A was modified with PEG using Acrl-PEG-NHS (Molecular weight of 3,400, 
Nektar Therapeutic, Huntsville, AL), which has two functional groups: the NHS group 
(N-hydroxylsuccinimide) is reactive towards lysine groups and is widely used for protein 
PEGylation; The Acrl (acrylate) group offers the possibility of vinyl polymerization, 
which can be used to tether con A to polymer chains, if needed.  Such tethering was not 
implemented in the present study.  Con A (Amersham Biosciences, Piscatway, NJ) was 
first dissolved in PBS at 15% (w/v).  Weighted Acrl-PEG-NHS was then slowly added 
to the con A solution at molar ratios of Acrl-PEG-NHS to con A of 5.0:1.0 and 2.5:1.0.  
The reaction was carried out in an ice bath for 30 minutes.  PEGylated con A tended to 
form white precipitates and compromised its ability to form glucose-responsive material 
with glycogen when left too long in the solution.  Hence, glucose-responsive materials 
were prepared immediately after the reaction.  The preparation of con A /PEG-con 
A-glycogen was based on the published protocol by Taylor et al.  Briefly, a con A 
solution with or without the step of PEGylation was mixed with a 30% glycogen (Sigma) 
solution, which was prepared by dissolving glycogen in PBS at 60% w/v followed by 
mixing with a 0.2 M NaIO4 (Sigma) solution at 1:1 volume ratio for 24 hours in the dark.  
This step converted the glycogen into the aldehydic form that would later react with the 
lysine groups on a con A molecules into a Schiff Base.  The viscous gel was formed 
immediately after stirring the mixtures of glycogen and con A and was left at room 
temperature 24 hours followed by 1 hour immersion in 1 mg/ml NaBH4 (Sigma) at 4°C, 
which stabilized the Schiff Base.  Finally, the gel was washed at least three times with 
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PBS buffer and stored in PBS at 4°C for later experiments.  
 
6.3.2 Glucose-responsiveness and leakage experiments 
 Con A-based materials were cut into pieces of similar size and weight and loaded 
into tissue culture inserts with membranes of 0.02-micron pore size (Nalge Nunc 
International, Rochester, NY) with 0.5 ml of PBS.  After putting each insert in a well of 
a 24-well plate, 0.5 ml PBS with different glucose concentrations (440, 220, 110, 55, 10, 
and 0 mM) was added to the well outside the inserts.  The final glucose concentrations 
in the wells were 220, 110, 55, 27.5 5, and 0 mM after equilibrium because equal volume 
of glucose-free PBS and glucose solution were added on the inside and outside side of the 
insert.  Pictures of gels were taken before and 30 minutes after the glucose solution was 
added.  After 6 hours of incubation, samples of solution were taken from each well 
outside the insert and analyzed for protein content by Coommassie Blue assay (Pierce, 
Rockford, IL).  Protein standards were constructed on the basis of known concentrations 
of con A. 
 
6.3.3 Cell culture and encapsulation 
 Stable, continuous insulin-secreting C2C12 mouse skeletal myoblasts were 
developed in a previous study reported in Chapter 5.  Cells were cultured as myoblasts 
in Dulbecco’s modified Eagle’s medium (DMEM, Mediatech, Herndon, VA) 
supplemented with 10% Fetal bovine serum (Hyclone, Logan, UT), 1% 
penicillin/streptomycin (Mediatech), and 1 µg/ml puromycin.  To facilitate cell loading 
into hybrid constructs, C2C12 cells were encapsulated in 2% alginate (ISP Inc., San 
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Diego, CA) at a density of 7x107 cells/ml of alginate following the general protocol 
published by Stabler et al [71], except that a poly-L-lysine membrane and a final alginate 
coating were not applied.   
 
6.3.4 Construct Experiments 
 To test the glucose-responsiveness of con A-based materials and to run cell-material 
hybrid construct experiments, a previously designed cell-material hybrid device with the 
geometry shown in Figure 5.2 was used but the constructs used in cell-free experiments 
are in smaller dimensions (Figure 6.1).  Briefly, two polycarbonate plates (3 mm in 
thickness), each with a hole in the center, constituted the main structural components of 
the construct.  Two silicon sheets (2 mm in thickness), also each with a hole in the 
center, were used to separate the membranes that enclosed the glucose-responsive 
material and the insulin source.  The material compartment was sandwiched between 
two insulin-permeable membranes, and the other compartment was sequestered on the 
other side by an insulin-impermeable membrane.   
For cell-free experiments, two 0.1 µm pore size polycarbonate membranes 
(Whatman Inc.) and a cellulose ester membrane of 6 kDa molecular weight cut off 
(Spectrum Lab, Rancho Dominguez, CA) were used.  Pieces of con A-based material of 
approximately 0.8 ml total volume were transferred by a spatula and used to fill the hole 
of the silicon sheet on top of a polycarbonate membrane.  Then, the other polycarbonate 
membrane was positioned on top of the material to complete the material barrier.   The 
material barrier with another silicon sheet and a cellulose ester membrane were then 
tightly assembled together by two polycarbonate plates and screws.  A 0.8 ml volume of 
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a 2 mg/ml FITC-insulin solution in PBS was then injected into the insulin compartment.  
The whole construct was immediately immersed in a beaker containing 20 ml of 0.2 
mg/ml BSA (Sigma) in PBS.  The beaker and the construct were then placed on top of 
an orbital shaker that provided adequate mixing.  2 hours after incubation, glucose was 
directly added to the beaker to increase the glucose concentration.  Samples were taken 
every 20 minutes during experiments, and the same amount of buffer was added back to 
maintain constant volume inside the beaker.  The purpose of cell-free experiment was 
mainly to characterize the change of insulin permeability of material after exposing to 
glucose, thus no step down of glucose was performed.  At the end of the experiment, 
fluorescence intensity of each sample was measured by a fluorescence plate reader 
(Spectra Max Gemini Plate Reader, Molecular Devices Corp., Sunnyvale, CA).  The 
concentrations of FITC-insulin were calculated using a standard curve constructed on the 
basis of known FITC-insulin concentrations.  These experiments were performed at 
room temperature.  
The membranes used in the cell-material hybrid construct were: a polyethersulfone 
membrane of 3kDa molecular cut off, positioned on the external side of the cell 
compartment, a 0.02 µm Anodisc membrane (Whatman Inc., Clifton, NJ), positioned 
between the material and the cells, and a 0.1 µm pore size polycarbonate membrane 
(Whatman Inc.) positioned between the material and the surrounding medium.  
Membranes used in cell-free experiments were different from the ones used in 
cell-material hybrid construct experiments because the latter tend to breakdown when 
assembled within the cell-free construct, which has smaller dimensions than the 
cell-material hybrid construct.  The experimental construct containing con A-based 
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material barrier was assembled as previously described, except approximately 2 ml of 
material was used.  For control experiments, the con A-based material was replaced with 
calcium alginate.  In these constructs, the material compartment was first assembled 
with the Anodisc and polycarbonate membranes and the polycarbonate plates 
sandwiching the silicon sheet tightly.  Sodium alginate (ISP Inc.) filter-sterilized through 
0.2 µm syringe filter (PALL Life Sciences), was then injected, filling the space in 
between the membranes.  The whole construct was immersed in a 1.1% CaCl2 solution 
for 30 minutes to ensure gelation of the alginate inside the membrane sandwich.  
 To assemble the cell compartment, 1 ml of alginate-encapsulated C2C12 cells were 
first placed on the top of the 3 kDa MWCO polyethersulfone membrane on the lower 
polycarbonate plate.  The material barrier was then laid on top of the cell compartment, 
followed by another polycarbonate plate laid on top of the compartments, and the whole 
construct was tightly assembled by screws.  Approximately 1 ml of the culture medium 
was then injected into the cell compartment.  The whole construct was immediately 
transferred into a beaker containing 50 ml of culture medium with 5 mM glucose 
supplemented 2.5% horse serum.  The beaker and the construct were then placed inside 
a tissue culture incubator on top of an orbital shaker that provided adequate mixing.  
To allow insulin to accumulate inside the cell compartment, each construct was 
cultured for 20 hours prior to glucose concentration changes.  At the end of this 
incubation period, the medium was replaced with fresh culture medium, so when the 
experiment started at t=0, the surrounding medium was insulin-free and contained 5 mM 
glucose.  For the glucose step up, 0.225 g of glucose was directly added to the beaker to 
increase the glucose concentration to 30 mM.  For the glucose step down, the medium 
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was completely replaced with fresh culture medium with 5 mM glucose.  Two 
square-waves of glucose were implemented to test the glucose-responsiveness of the 
hybrid construct.  Samples were collected every 30 minutes during experiments, and the 
same amount of culture medium was added back to maintain constant volume inside the 
beaker.  All samples were stored at -20oC for later insulin assay.  At the end of the 
experiment, the constructs were disassembled, and the alginate-encapsulated cells were 
collected to assess cell viability. 
 
6.3.5 Analytical Techniques 
To verify that Acrl-PEG-NHS molecules indeed conjugated to con A molecules, the 
fluorescamine (Sigma) assay [161] was used.  Fluorescamine reacts with primary 
amines such as lysine to form a fluorescent product.  As more PEG molecules attached 
to a con A molecule through the reaction between NHS and lysine groups, fewer primary 
amine groups were available for fluorescamine.  Immediately after PEGylation of con A, 
the PEgylated con A solution was diluted with PBS into different concentrations ranging 
between 15-300 µg/ml.  After dilution, 150 µl aliquots of samples were pipetted into the 
wells of 96-well plates, and 50 µl of 3 mg/ml fluorescamine dissolved in acetone was 
then added to each well.  The fluorescence was determined by a fluorescence plate 
reader (Spectra Max Gemini Plate Reader, Molecular Devices Corp., Sunnyvale, CA).  
Fluorescence intensity was later plotted as a function of concentration.  Slopes were 
obtained for both modified and unmodified con A samples.  The slop ratio of PEG-con A 
to unmodified con A was calculated and prorated to the number of primary amine groups 
(12 lysine groups plus one terminal amine group) in Con A to determine the extent of 
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modification.     
  
6.3.6 Cell viability and insulin assay 
To measure the viability of alginate-encapsulated cells, beads were dissolved in a 
2.2% sodium citrate solution, and the resulting cell suspension was centrifuged for 3 
minutes at 110g.  Pelleted cells were re-suspended in culture medium and mixed with 
trypan blue (Sigma) at 1:1 volume ratio.  Cell viability in the final suspension was 
determined on a hemocytometer under a microscope by trypan blue exclusion.  Insulin 
in cell-material hybrid construct experiments was assayed by a human-specific insulin 



















Figure 6.1 Configuration of constructs used in cell-free experiments.  The con 
A-glycogen material was placed in the 2.0 cm diameter hole of a 2 mm-thick silicon sheet 
and was sandwiched between two 0.1 µm pore-size polycarbonate membrane.  The 
insulin compartment consisted of 2 mg/ml FITC-insulin solution positioned in the 2.0 cm 
diameter hole of a 2 mm-thick silicon sheet and bounded on one side by the material 
compartment and on the other side by a 6k Dalton MWCO cellulose ester membrane.  
Polycarbonate plates with 6 screws were used to fix everything in place.  The figure is 
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6.4 Results  
 PEGylation of Con A molecules was verified by the fluorescamine assay and a 
typical result is shown in Figure 6.2.  The slope ratio of PEG: con A (molar ratio 5) to 
unmodified con A is 62.7±9.2%, which indicated that an average of four to five lysine 
groups per con A molecule were reacted with PEG molecules after the reaction (13 
primary amine groups per con A molecule x(1-62.7%) =4.8).  Similar calculation was 
done with PEG: con A (molar ratio 2.5) and a slope ratio of 82.7±3.1 was obtained, which 
indicated that about two to three PEG molecules is attached to one con A molecules (2.2).  
The notation of “PEG 2.5-Con A” and “PEG 5-con A” will be used for PEG/con A molar 
ratio of 2.5 and 5, respectively.   
Shortly after mixing the glycogen and PEG-con A solutions, a viscous gel was 
formed. The gel formed with PEGylated con A was softer and less opaque compared to 
the gel formed with unmodified con A.  Within 30 minutes after exposing the gels to 
different glucose concentrations, the PEG 5-con A-glycogen material remained as gel at 5 
mM glucose but turned into a sol at 27.5 mM glucose, whereas the PEG 2.5-con 
A-glycogen material was partially converted to sol at 55 mM glucose and completely 
converted to sol at 110 mM.  Most of the unmodified con A-glycogen material remained 
in the gel state at glucose concentrations tested (Figure 6.3). These results thus indicated 
that the glucose-responsiveness of the con A-based material can be improved by using 
PEGylated con A.  PEGylation of con A is expected to increase the molecular weight of 
con A molecules, and hence decrease its permeability through membranes.  However, 6 
hours after exposing the gel to different glucose concentrations, higher protein 
concentrations were detected outside the 0.02-µm pore size tissue culture inserts at 0-55 
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mM glucose when PEGylated con A was used relative to unmodified con A (Figure 6.3).   
Experiments with FITC-labeled insulin were carried out at room temperature and 20 
ml PBS with 0.2 mg/ml BSA as the surrounding solution.  The construct was incubated 
in glucose-free PBS for 2 hours, during which time the material was in the gel state.  
Then, glucose were added into the beaker to increase the glucose concentration and the 
experiments were continued for another 2 hours.  The FITC-insulin release rates during 
glucose-free and high-glucose periods were calculated by the slopes of the least squares 
fit of the released FITC-insulin concentration vs. time data; rates at high glucose periods 
were normalized to the corresponding glucose-free release rate during the 0-2 hour period.  
The results from three independent experiments were shown in Figure 6.4.  The change 
of FITC-insulin release rates from 0 to 27 mM glucose was most pronounced with PEG 
5-con A-glycogen material, indicating that material formed with PEG 5-con A-glycogen 
can be used to control insulin release at glucose concentrations close to the physiologic 
range.  
 As PEG5-con A-glycogen exhibited glucose responsiveness closest to the 
physiologic range, it was the material used in construct experiments with cells.  Figure 
6.5 (A, B and C) show a typical insulin-release profile from the cell-material hybrid 
construct containing three different types of materials: PEG5-con A-glycogen, alginate, 
and con A-glycogen, under glucose square-wave changes from 5 to 30 to 5 mM.  The 
average insulin release rate in each glucose concentration was calculated from the slope 
of the least squares fit of the released insulin concentration vs. time data; each rate was 
normalized to the corresponding low-glucose release rate during the 0-2 hour period, 
which was set equal to 1.  The results from three independent experiments are shown in 
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Figure 6.6.  Statistical differences were evaluated by the Student’s t-test and were 
considered significant at p<0.05.  Constructs containing alginate or unmodified con 
A-glycogen material acted as continuously insulin-release devices, as they did not 
respond to changes in the surrounding glucose concentration.  On the other hand, insulin 
release rates from the construct containing PEG 5-con A-glycogen changed with the 
implemented step changes of glucose concentration:  the rates during high glucose were, 
on average, 2- to 3- fold higher than those during the low glucose periods.   However, 
we also noticed that the PEG 5-con A-based material became more fluid after 32 hours of 
experiment. 
 At the end of 32 hour-long incubations, cell viabilities from constructs containing 
different types of material barriers were evaluated by trypan blue and are shown in Figure 
6.7.  When constructs were exposed to 5-30 mM glucose, only 20% of cells remained 
viable after 32 hours in all types of construct.  Viabilities were significantly higher in 
constructs containing alginate or con A-glycogen and cycled between 25 and 220 mM 
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Figure 6.2 Linear regression analysis of fluorescamine standard curves for nature and 
























Figure 6.3 Con A-based glucose-responsive materials before (top) and 30 minutes after 
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Figure 6.4  Amount of con A molecules passed through 0.02-µm pore size membrane 
tissue-culture inserts 6 hours after exposing to glucose solutions (n=3).  # * and +  
indicate pair-wise statistical comparisons using a one-tailed t-test, p<0.05.  Error bars 
































































































Figure 6.5 FITC-insulin release rates from cell-free constructs containing different types 
of con A-based materials in different glucose concentrations relative to those in 
glucose-free solutions (materials at gel state) (n=3).  # *§ ¤ and ♦ indicate pair-wise 







































Figure 6.6 Typical insulin-release profiles from hybrid constructs of 
alginate-encapsulated insulin-secreting C2C12 cells with PEG 5-con A-glycogen (A), 



















































































































Figure 6.7 Insulin-release profiles from hybrid constructs of alginate-encapsulated 
insulin-secreting C2C12 cells with PEG 5-con A-glycogen (filled bar), alginate (dashed 
bar), and con A-glycogen (blank bar).  In each independent experiments, insulin release 
rates were normalized to the rate during 0-2 hours, which was set equal to 1 (n=3). * 
indicate pair-wise statistical comparisons using a one-tailed t-test, p<0.05.  Error bars 


























25 mM - 220 mM
 
Figure 6.8 Viabilities of alginate-encapsulated C2C12 cells at the end of construct 
experiments (n=3).  Filled bars are experiments performed under 5-30 mM glucose 
square-wave changes; Dashed bars are data obtained from the previous experiments 
under the same experimental set up except the glucose square-wave changes were 









6.5 Discussion  
Previously, we developed a cell-material hybrid pancreatic construct in which the 
kinetics of insulin release are dominated by the phase changes of glucose-responsive 
material.  Cells inside the construct can be different types of non-β cells retrieved from a 
patient and engineered for insulin expression, and they act as continuous, unregulated 
insulin secretors.  As the cells are of autologous origin, they relax the 
immune-acceptance problems intrinsic to the use of xeno- or allogeneic cells.   Since 
the release of insulin from the construct is mainly controlled at the material level, the 
functionality of the glucose-responsive material, including the glucose sensitivity, 
kinetics, and reversibility of phase changes, are keys to the development of such 
construct.  We have chosen a con A-based glucose-responsive material in our 
proof-of-concept experiments because it has high specificity towards glucose, shorter 
response time relative to other types of glucose-responsive hydrogels, and it functions 
with insulin secreted by the cells.  However, several issues remained with the con 
A-glycogen material that need to be addressed, in particular, bringing the glucose 
sensitivity of the gel towards physiologically relevant glucose concentrations.  
When exposing a con A-glycogen hydrogel to a glucose solution, the binding states 
of the con A molecules can be described in the following equations: 
[con A] + [glycogen] ↔ [con A:glycogen] 
[con A] + [glucose] ↔ [ con A:glucose] 




glycogenAconK glycogenAcon =  
[con A:glycogen]=Kcon A:glycogen[con A][glycogen]             (1) 
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egluAconK egluAcon =  
[con A: glucose]=Kcon A:glucose [con A][glucose]                (2) 






eA:glucon coscos cos=                   (3) 
To have the material in the sol state, most of the con A molecules have to bind to the free 
glucose, in other words, [con A:glucose] has to be larger than [con A: glycogen].  As 
shown in equation (3), the situation can be achieved by increasing the concentration of 
free glucose.   However, due to multivalency effects, con A generally has higher affinity 
towards polysaccharides than towards free glucose (e.g. KconA:dextran=1.5x104 M-1 and 
KconA:glucose=320 M-1 [162]), hence, the glucose concentration required to induce the con 
A-glycogen gel into a sol is high beyond physiological range.  One potential solution in 
improving the glucose sensitivity of the con A-based glucose-responsive material is by 
adjusting the binding constants, more specifically, decreasing the KconA:glycogen and 
increasing Kcon A: glucose.  
Inspired by the results reported by Park et al [8], which indicated that PEGyled con 
A molecules increased their binding affinity towards free glucose and possibly reduced 
their binding affinity towards polysaccharides through steric hindrances, we hypothesized 
that the glucose responsiveness of developed con A-glycogen system can be improved by 
using PEGylated con A molecules.  Results were quite promising in terms of improving 
the sensitivity of con A-glycogen material:  the hydrogel formed by PEG 5-con 
A-glycogen turned into a sol at a glucose concentration as low as 28 mM.  In addition, 
using PEG 5-con A based material in our proposed cell-material hybrid construct, we 
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were able to convert the constitutively insulin-secreting characteristics of genetically 
engineered myoblasts into a glucose-responsive insulin release from the device under the 
square -wave changes of glucose concentrations between 5 mM and 30 mM.  
The con A molecule has twelve lysine groups and only one lysine group is located 
within the saccharide-binding site of con A.  Although different studies have reported 
that modifying con A molecules through lysine groups does not compromise the 
glucose-binding properties of con A molecules [163, 164], little is known as to which 
lysine group among the twelve or number of lysine groups being modified has the most 
impact on the functionality of con A molecules.  For instance, there is evidence that 
acetylation of con A molecules through lysine residues leads to the disruption of salt links 
between 114 and 116 lysine groups, and consequently, dimeric instead of tetrameric con 
A molecules were formed at pH 7 [32, 165].  It is known that the binding affinity of 
dimeric con A towards polysaccharides is lower than that of tetrameric con A [166, 167].   
As the conjugation of PEG molecules via covalent attachment to the lysine groups of con 
A is not a site-specific reaction, the random PEGylation of Con A molecules could result 
in different types of con A molecules, including molecules that have higher binding 
affinity toward free glucose as shown by Park et al [8]; molecules that have lower binding 
affinity toward polysaccharides due to steric hindrance of PEG molecules; and dimeric 
instead of tetrameric con A molecules at neutral pH, which are known to have lower 
binding affinity toward polysaccharides.  Clearly, more experiments are needed to 
further understand the exact underlying cause(s) of the improved glucose sensitivity of 
the material. 
Based on the above discussion, PEGylation of con A could lead to an improvement 
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of glucose sensitivity of the resulting gel but also cause con A molecules to be easily 
dissociated from the gel structure under low glucose concentration.  This provides the 
possible explanation that even though the PEGylation is expected to increase the 
molecular weight of con A and hence decrease its permeability through porous 
membranes, results from the leakage experiments showed that some con A molecules 
leaked out the system at glucose concentration as low as 27.5 mM.  Although Ueno et al 
[168] showed that the PEGylated con A has reduced immunogenicity, leak of PEGylated 
con A in the body is still possible to induce immune response.   In addition, as con A is 
the key element in retaining the glucose responsiveness of the hydrogel, loss of con A 
will compromise the stability of the material.  Hence, tethering PEGylated con A to the 
polysaccharides constitutes a critical issue in improving both the biocompatibility and 
stability of the material.  
The fold differences of insulin-release rates between high and low glucose 
concentrations between cell-free (7-fold) and cell-material hybrid construct (3-fold), can 
be attributed from differences in experimental conditions: FITC-insulin vs. insulin 
secreted by the cells, surrounding solutions, temperature, and whether there was a 20 
hours of incubation time in 5 mM culture medium prior to glucose-square wave changes.  
Another notable finding was the significant loss of cell viability at the end of the 32 
hour-long experiments, which we did not observe with previous experiments performed 
under high glucose square-wave changes.  Since there was no significant difference 
between the control (both alginate and con A-glycogen) and experimental constructs 
(PEG 5-con A-glycogen), we speculate the loss of cell viability to be due to the 
unfavorable conditions of hypoglycemia inside the constructs.  Modifications aimed at 
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improving the construct design such as enhancing the nutrient-transport by increasing the 
surface to volume ratio are described in Chapter 7 of this thesis.   
Smart hydrogels that undergo phase transition in response to specific molecules 
have many technological applications in sensors, drug delivery devices and actuators.  
The study presented here showed that it is possible to improve the glucose responsiveness 
of con A-based material by altering the binding affinity of con A molecules through 
PEGylation.  Moreover, by associating the improved con A-based hydrogel with 
genetically engineered cells, we further demonstrated the possibility of utilizing the 






















Cell source constitutes a major problem in developing a tissue engineered pancreatic 
substitute, and one of the major selection criteria is how cells secrete insulin in response 
to stimuli.  In this thesis, we have contributed to this field by characterizing and 
improving the secretion properties of continuous-β cells and cells of non-β origin.  A 
concern with the use of β-cell lines is that cells continue to grow post-encapsulation, and 
due to nutrient limitation, the homogenous distribution of the cells within the construct 
remodel in long-term culture.  In Chapter 3, we attempted to understand whether the 
remodeling process within the alginate-encapsulated βTC cells has any effects on the 
insulin-secretion profile of the capsules.  Studies showed that the secretion profile from 
the beads indeed changed after long-term culture, and that the changes can be prevented 
if cell growth was inhibited.  Although the clinical relevance of this study is not fully 
understood, as whether the change of insulin secretion dynamics has any effect on the in 
vivo efficacy of the capsules, the results pointed out that the remodeling process within 
the construct could leads to the functional changes of the implants, and growth inhibition 
with continuous β-cell lines appeared to be necessary not only to prevent overgrowth in 
vivo but to prevent any unwanted alterations of secretion dynamics.   
In the second part of the thesis, we proposed a novel idea of improving the secretion 
properties of genetically engineered cells of non-β origin.  In this, glucose 
responsiveness was built into the system at the material level instead of relying on 
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transcriptional control at cellular level.  Con A-based glucose-responsive material was 
identified as a suitable material for our proof-of-concept experiments.  Two of the non-β 
cells, human HepG2 hepatoma and murine C2C12 myoblasts, were genetically 
engineered to become constitutively insulin secretors.  Loading these cells into the 
proposed prototype of cell-material hybrid construct, which contained con A-glycogen in 
the material barrier, the continuous insulin-secretion property from the cells changed into 
a glucose-responsive, more physiologically relevant, insulin-release device.  The 
advantages of such hybrid construct are as follows: (1) different types of non-β cells can 
be retrieved from the patient as biopsy thus eliminating the concern of cell availability; (2) 
cells are of autologous origin and of non-β cell phenotype, which relaxes the immune 
acceptance problems intrinsic to the use of xeno or allogeneic cells and autoimmunity 
towards β cells; (3) this approach aims at genetically engineering cells ex vivo, which 
prevents any potential concerns of in vivo gene therapy, such as the immunogenecity of 
gene-delivery vehicles;  (4) the sluggish secretion property of genetically engineered 
non-β cells is improved by the use of glucose-responsive materials, more physiologic 
insulin release by the device; (5) the construct offers the advantages of retrievability if 
needed; (6) cells act as continuous insulin secretor, patients will have better life-styles 
without the use of needles for insulin-injection or the burden of refilling insulin pumps.  
 As the con A-glycogen material used in the proof-of-concept experiments 
undergoes phase changes at glucose concentrations exceeding physiological ranges, the 
last part of the thesis aimed at improving the glucose sensitivity of con A-based material.  
Studies showed that the glucose sensitivity of the hydrogel formed by PEG 5-con A and 
glycogen was closer to physiological ranges than that of the material formed by 
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unmodified con A, which presented the possibility of developing a glucose-responsive 
material with proper sensitivity through the modifications of glucose-binding molecules.  
The hybrid construct containing PEG-5 con A-glycogen and genetically-engineered 
continuous insulin-secreting C2C12 cells exhibited glucose-responsive insulin release 
under glucose concentrations closer to physiological ranges, indicating the feasibility of 
developing a proper tissue engineered pancreatic construct based on glucose-responsive 
materials and insulin-secreting cells.     
 
7.2 Future directions 
7.2.1 Continuous β cell lines  
Just as islets from different species exhibit different biphasic insulin-secretion 
patterns upon glucose stimulation, such as the ones between mouse and rat (mouse islets 
exhibit a sharp first phase of secretion, with the second phase of insulin release being at a 
flat and much lower rate than the maximum rate of the first secretion phase; and rat islets 
have the insulin secretion rate during the second phase comparable to the maximum rate 
of the first phase [119]), in vivo studies are needed to understand whether the subtle 
changes in insulin-secretion profile from alginate-encapsulated continuous-cell lines with 
time could result in compromised glycemic regulation in small and, more importantly, 
large animal models.   
Furthermore, as the remodeling processes were the consequences of series events, 
including the development of nutrient gradients within the beads, accumulation of cell 
death byproducts, degradation of the supporting matrix, and changes of the cell-cell and 
cell-matrix interactions from those in freshly encapsulated preparations, identifying the 
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exact cause of the secretory profile changes with time would be interesting and 
significant for the use of continuous-cell lines as the insulin source.   
 
7.2.2 Development of cell-material hybrid constructs 
The proposed cell-material hybrid construct is the first attempt in combining 
glucose-responsive materials with insulin-secreting cells for a tissue-engineered 
pancreatic substitute.  Clearly, there remain many issues with the construct that need to 
be addressed prior to any in vivo studies.  The following paragraphs discuss possible 
future directions for the construct development.  
  
7.2.2.1 Improving properties of glucose-responsive material 
The key factor in developing the proposed cell-material hybrid construct is the 
functionality of the glucose-responsive material.  The current con A-based material is 
only suitable for proof-of-concept experiments and needs to be improved prior to any 
clinical applications. 
The first issue is the glucose sensitivity of con A-based material, which needs to be 
in the range of 5-16 mM glucose.  Studies shown in Chapter 6 indeed presented a 
possibility in improving the glucose-sensitivity of con A-based hydrogel through the 
PEGylation of con A molecules.  However, as the PEG-NHS reacted randomly with the 
12 lysine groups on a con A molecule, little is known at the molecular level as to which 
lysine or the number of lysine groups that need to be modified to obtain a con A molecule 
with proper binding affinity, both towards free glucose or polysaccharides, for forming a 
sensitive material.  On the other hand, it is known that the con A molecule has different 
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binding-affinity towards different types of polysaccharides, for example, it has higher 
affinity towards branched polysaccharides than toward linear polysaccharide chains [169].  
Using other types of polysaccharides in the system constitutes another approach in 
improving the glucose sensitivity of the con A-based hydrogel.  Overall, a thorough 
understanding of glucose-binding molecules in conjunction with the use of different types 
of polysaccharides constitute promising future approaches for improving the 
glucose-sensitivity of con A-based materials. 
A second issue is how fast the material undergoes phase changes.  The response 
time of 2 mm thick con A-based glucose-responsive material was approximately 30 
minutes from gel to sol and possibly longer from sol to gel.  As the idea of using the 
glucose-responsive material to control the release of insulin secreted from the cells is that 
the kinetics of phase change of material are faster than those of the cells in response to 
stimuli, and a proper pancreatic substitute should have insulin-secretion kinetics similar 
to those of the normal β cells, 30 minutes of time lag is not clinically relevant.  The 
response time could be reduced by reducing the thickness of the material barrier, and 
more work needs to be done in defining a proper thickness of the gel that gives a fast 
response time without compromising its glucose responsiveness. 
Finally, con A is known to be immunogenic and toxic to cells, and it is the major 
glucose-sensing element in the system, thus it has to be retained permanently and 
maintained active so the material can undergo phase changes repeatedly.  Nonetheless, 
with the current set up, con A tends to leak out when the material is in the sol state.  
Thus, to improve the biocompatibility and stability of the con A-based material, con A 
has to be tethered to the polysaccharide chain so it will not diffuse out.  The approach 
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presented in Appendix 2 is a possible reaction scheme for tethering con A molecules to 
the polysaccharide chains, in which the PEG-con A is tethered to the polysaccharides 
through the covalent bonding of acrylate group on the PEG to GEMA during radical 
polymerization.  Nonetheless, this approach as well as others requires further 
understanding as to whether the tethering will compromise the glucose-binding properties 
of con A molecules or reduce the glucose-responsiveness of the resulting hydrogels.  
 
7.2.2.2 Improving the design of cell-material hybrid construct 
 The other critical component of the proposed hybrid construct is the cells being used.  
In this thesis, cells being used were constitutive insulin secretors, however, it might be 
advantageous to prevent over accumulation of insulin inside the construct by using 
hepatic cells that are glucose-responsive with insulin-feedback inhibition, such the one 
developed by Thule et al [84].  The only concern in using hepatic cells is that it is yet 
quite difficult to maintain primary hepatocytes ectopically.  In this case, myoblasts 
might be a better option as the insulin source.  Myoblasts are relatively easy to be 
retrieved as biopsy from a patient, propagated and engineered ex vivo, and differentiated 
into myotubes as a stable living protein-delivery vehicle.  However, as reported in the 
literature [95] and in Chapter 5, myoblasts cannot differentiate into myotubes and 
recombinant protein secretion is decreased when these cells are encapsulated in alginate.  
Thereby, to facilitate the loading of stable insulin-secreting myoblasts into the hybrid 
construct, differentiation of myoblasts into stable myotubes in different types of 
biomaterials needs to be further investigated.  
In terms of the design of the construct, the size of the current proposed prototype is 
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similar to the size of the implantable insulin pump produced by Metronics [170], which 
can be implanted into the peritoneal cavity.  However, it appears that the transport rate 
of nutrients is not sufficient to maintain the cells inside the construct, thus thinner 
insulin-impermeable surroundings with large surface to volume ratio need to be used and 
evaluated.  Alternatively, one could investigate the possibility of further designing the 
glucose-responsive material so that it can be used to coat the encapsulated cells with a 
thin layer, in which the pore sizes are regulated by the glucose, hence achieving 



















A1. Improving the glucose sensitivity of con A-based material by incorporation of 
glucose oxidase2 
Con A exists as tetramer at pH above 7 and as a dimer at pH below 6.  Each 
monomer binds independently to ligand such as glucose.  Thus, when con A is mixed 
with polysaccharides (e.g. glycogen) at neutral pH, it acts as a crosslinker and a viscous 
gel is resulted.  When the con A-based material is exposed to a low pH environment, 
tetrameric con A dissociates into dimeric con A, which then causes the gel to be less 
crosslinked with higher insulin permeability (Figure A1 and A2).   
Based on this unique property, it was hypothesized that one could improve the 
glucose sensitivity of the con A-based material by incorporating GluOx into the con 
A-based material.  Similar to the design principle of glucose-responsive material based 
on GluOx, when the material is exposed to an increase of glucose concentration, GluOx 
within the hydrogel reacts with glucose, which then causes the pH within the hydrogel to 
drop.  The lower pH within the hydrogel then leads to the dissociation of tetrameric con 
A into dimeric con A and causes the gel structure to be less crosslinked and more ready to 
be broken down by free glucose.  Moreover, the binding affinity of dimeric con A is 
known to be smaller than that of tetrameric con A towards polysaccharides, thus the 
glucose concentration required to cause the gel to sol phase change is expected to be 
lower.   
_ 
__________________________________ 
2 Experiments were performed by the undergraduate research scholar, Angela Chu. 
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Preparation of con A-based material was based on the protocol described in Chapter 
4 of this thesis, except various amount of GluOx (Sigma) was dissolved with con A in 
PBS prior to the mixing of con A with glycogen.  Figure A3 shows the decrease of pH 
with time in wells of a 96-well plate containing con A-based materials incorporated with 
various amount of GluOx in different glucose concentrations.  pH was measured by pH 
indicator strips (EMD Chemical Inc., Gibbstown, NJ).  Results indicated that GluOx 
remained active when entrapped inside the con A-based material:  it reacted with 
glucose and produced gluconic acid, which then lowered the pH in the surrounding 
environment.  
As tested in a diffusion chamber experiment (experimental set up is described in 
Chapter 4 of this thesis) using FITC-insulin as the insulin source, incorporating GluOx 
into the con A-based material at 1 mg/ml did not compromise the glucose responsiveness 
of the con A-based material.  Con A-based material with or without GluOx exhibited 
similar changes of FITC-insulin diffuse rate when materials were exposed to a 4% 
glucose step up at t=2 hour and a glucose step down at t=5 hour (Figure A4).  However, 
in experiments having a lower glucose step change that is closer to physiological range 
(e.g. 0.5 % at t=2 hour, Figure A5), no significant changes in FITC-insulin flux was 




















      
 
        
             
Figure A 1. Schematic of con A-based material exposed to low pH environment.  Con A 



























































Figure A 2.  Accumulation of FITC-insulin in the receiver compartments of two 
diffusion apparatus (experimental set up is described in Chapter 4) containing 
FITC-insulin in the donor compartments at different pH.  At pH 3.2, due to the 
formation of dimeric con A instead of tetrameric con A, con A-based material was less 





























































Figure A 3.  Changes of pH with time in different glucose solution containing con 
A-based material incorporated with (a) 0 mg/ml (b) 1 mg/ml (c) 2.5 mg/ml (d) 5 
mg/ml (e) 7.5 mg/ml (f) 10 mg/ml of GluOx.  
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Figure A 3.  Changes of pH with time in different glucose solution containing con 
A-based material incorporated with (a) 0 mg/ml (b) 1 mg/ml (c) 2.5 mg/ml (d) 5 mg/ml (e) 







































































































Figure A 4.  Accumulation of FITC-insulin in the receiver compartments of two 
diffusion apparatus containing FITC-insulin in the donor compartment.  Con A-based 








































0.5% glucose step up
 
Figure A 5.  Accumulation of FITC-insulin in the receiver compartments of two 
diffusion apparatus containing FITC-insulin in the donor compartment.  Con A-based 


















A2.  Glucose responsive material based on con A and GEMA 
Preparation of poly(GEMA) and con A-based glucose-responsive material was 
based on the general protocol published by Miyata et al [142].  Briefly, 0.1 ml of 
glucosyloxyethyl methacrylate (GEMA) (Nippon Fine Chemcial, Osaka, Japan) mixed 
with 1.9 ml of PBS was used to dissolve 15 mg of con A, and 0.01 g of initiator, 
2,2’-Axobis(2-amidinopropance) dihydrochloride (AIBA) (Sigma).  To remove radical 
scavenger such as oxygen, the mixture was purged with nitrogen for 1 hour prior to 
polymerization.  After exposing the mixture to UV light for 30 minutes, a whitish gel 
was resulted.  The gel appeared to be more elastic than the material formed with 
glycogen and con A.  To test whether the con A-poly(GEMA) gel exhibit glucose 
responsiveness, the gel was cut into pieces of similar size and loaded into a well of a 
24-well plate.  1 ml of glucose solution (220, 110, 55, 25 and 0 mM) was then added 
into each well.  Pictures were taken prior to and an hour after glucose solution was 
added (Figure A6 a and b).  Results indicated that the material turned into a sol at 
glucose concentrations between 110 and 220 mM.  
To prevent con A leakage during phase changes, a reaction scheme was proposed to 
tether con A molecules to polysaccharides.  In this, Acryl-PEG-con A, prepared as 
described in chapter 6, was used to mix with GEMA and AIBA in PBS in the same 
composition as described above.  The idea was that during polymerization, the acrylate 
group on a PEGylated con A would react with the acrylate group on a polyGEMA, and 
thus tethering con A to the polysaccharides.  However, no gel formation was observed in 
reactions using PEG 2.5-con A or PEG 5-con A.  More experiments are needed to 





















Figure A 6.  Con A-GEMA glucose responsive material before (a) and one hour after 
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